bimatoprost profile

Bimatoprost: A cloprostenol-derived amide that is used as an ANTIHYPERTENSIVE AGENT in the treatment of OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	5311027
CHEMBL ID	1200963
CHEBI ID	51230
SCHEMBL ID	24425
MeSH ID	M0395184

Synonym
CHEBI:51230 ,
(5z)-7-{(1r,2r,3r,5s)-3,5-dihydroxy-2-[(1e,3s)-3-hydroxy-5-phenylpent-1-en-1-yl]cyclopentyl}-n-ethylhept-5-enamide
bimatoprostum
gtpl1958
LS-181817 ,
latisse
5-heptenamide, 7-(3,5-dihydroxy-2-(3-hydroxy-5-phenyl-1-pentenyl)cyclopentyl)-n-ethyl-, (1r-1(alpha(z),2beta(1e,3s*)3alpha,5alpha))-
5-heptenamide, 7-(3,5-dihydroxy-2-(3-hydrdoxy-5-phenyl-1-pentenyl)cyclopentyl)-n-ethyl-, (1r-(1alpha(z),2beta(1e,3s*),3alpha,5alpha))-
lumigan
agn 192024
(z)-7-((1r,2r,3r,5s)-3,5-dihydroxy-2-((1e,3s)-3-hydroxy-5-phenyl-1-pentenyl)cyclopentyl)-n-ethyl-5-heptenamide
agn-192024
5-heptenamide, 7-((1r,2r,3r,5s)-3,5-dihydroxy-2-((1e,3s)-3-hydroxy-5-phenyl-1-pentenyl)cyclopentyl)-n-ethyl-, (5z)-
latisse (tn)
D02724
lumigan (tn)
155206-00-1
bimatoprost (jan/usan/inn)
15m ,
(5z)-7-{(1r,2r,3r,5s)-3,5-dihydroxy-2-[(1e,3s)-3-hydroxy-5-phenylpent-1-enyl]cyclopentyl}-n-ethylhept-5-enamide
NCGC00181745-01
bimatoprost
DB00905
CHEMBL1200963
prostamide
(z)-7-[(1r,2r,3r,5s)-3,5-dihydroxy-2-[(e,3s)-3-hydroxy-5-phenylpent-1-enyl]cyclopentyl]-n-ethylhept-5-enamide
qxs94885mz ,
unii-qxs94885mz
bimatoprost [usan:inn:ban:jan]
AKOS015995566
bimatoprost [inci]
bimatoprost [ema epar]
bimatoprost [mart.]
bimatoprost component of ganfort
ganfort component bimatoprost
bimatoprost [vandf]
(z)-7-[(1r,2r,3r,5s)-3,5-dihydroxy-2-[(1e,3s)-3-hydroxy-5-phenyl-1-pentenyl]cyclopentyl]-n-ethyl-5-heptenamide
bimatoprost [usan]
bimatoprost [inn]
bimatoprost [who-dd]
5-heptenamide, 7-(3,5-dihydroxy-2-(3-hydroxy-5-phenyl-1-pentenyl)cyclopentyl)-n-ethyl-, (1r-1(.alpha.(z),2.beta.(1e,3s*)3.alpha.,5.alpha.))-
bimatoprost [mi]
bimatoprost [jan]
bimatoprost [orange book]
durysta
AM84507
HY-B0191
17-phenyl trinor prostaglandin f2alpha ethyl amide
smr000058996
MLS006010039
SCHEMBL24425
AQOKCDNYWBIDND-FTOWTWDKSA-N
FD10460
(5z)-7-[(1r,2r,3r,5s)-3,5-dihydroxy-2-[(1e,3s)-3-hydroxy-5-phenylpent-1-en-1-yl]cyclopentyl]-n-ethylhept-5-enamide
SR-01000942224-1
sr-01000942224
mfcd03411999
17-phenyl-tri-norprostaglandin f2alpha-ethyl amide, >=95%, solid
us9271961, bimatoprost
bdbm220120
EX-A1769
DTXSID30895042 ,
AS-35082
Q2393348
5-heptenamide, 7-[(1r,2r,3r,5s)-3,5-dihydroxy-2-[(1e,3s)-3-hydroxy-5-phenyl-1-penten-1-yl]cyclopentyl]-n-ethyl-, (5z)-
NCGC00181745-03
(5z)-bimatoprost
(e)-7-[3,5-dihydroxy-2-[(e)-3-hydroxy-5-phenylpent-1-enyl]cyclopentyl]-n-ethylhept-5-enamide
EN300-21680860
bimatoprost in bulk
B6165
bimatoprost (mart.)
5-heptenamide, 7-((1r,2r,3r,5s)-3,5-dihydroxy-2-((1e,3s)-3-hydroxy-5-phenyl-1-pentenyl)cyclopentyl)-n-ethyl-,(5z)-
s01ee03
dtxcid401324598
(5z)-7-((1r,2r,3r,5s)-3,5-dihydroxy-2-((1e,3s)-3-hydroxy-5-phenylpent-1-en-1-yl)cyclopentyl)-n-ethylhept-5-enamide

Excerpt	Reference	Relevance
"Bimatoprost is a synthetic prostaglandin structural analogue used among other indications to increase eyelash growth. "	( Topical bimatoprost in the treatment of eyelash loss in alopecia totalis and universalis: A prospective, open-label study. Cetkovska, P; Hordinsky, M; Ricar, J; Ricarova, R, 2022)	2.6
"Bimatoprost is a synthetic prostamide F"	( Bimatoprost promotes satiety and attenuates body weight gain in rats fed standard or obesity-promoting diets. Chuang, CL; Loomes, K; Poloso, NJ; Raymond, I; Spada, C; Tong, W; Vu, C; Walker, C; Woodward, DF, 2022)	3.61
"Bimatoprost 0.03% is an intraocular pressure (IOP) lowering prostaglandin analog with different adverse side effects such as potential ocular inflammatory effect and ocular hyperemia."	( Granulomatous uveitis and choroidal detachment in a patient after topical treatment with Bimatoprost: A case report. Anna, F; Bordinone, MA; Massimo, L; Micelli Ferrari, L; MicelliFerrari, T; Nikolopoulou Gisotti, E; Zito, R, 2022)	2.39
"Bimatoprost is an ophthalmic prostamide analog that is approved by the United States Food and Drug Administration for the treatment of eyelash hypotrichosis."	( Therapeutic potential of bimatoprost for the treatment of eyebrow hypotrichosis. Chanasumon, N; Sriphojanart, T; Suchonwanit, P, 2018)	1.51
"Bimatoprost is a prostaglandin F2α analog and is often used for eyelash growth for cosmetic reasons as well as in the treatment of glaucoma."	( Open-label pilot study to evaluate the effectiveness of topical bimatoprost on rhododendrol-induced refractory leukoderma. Fukaya, S; Fukuyasu, A; Hayashi, K; Iimuro, S; Ishikawa, T; Kamata, M; Kasanuki, T; Ohnishi, T; Tada, Y; Takeoka, S; Tanaka, T; Watanabe, S; Yokobori, M, 2018)	1.44
"Bimatoprost is a prostaglandin analogue used topically in the treatment of glaucoma. "	( Bimatoprost (0.03%)-induced accommodative spasm and pseudomyopia. Padhy, D; Rao, A, 2015)	3.3
"Bimatoprost is a potent hypotensive drug used in the treatment of glaucoma or ocular hypertension with lower target intraocular pressure (IOP) than latanoprost. "	( Incidence of hyperemia associated with bimatoprost treatment in naïve subjects and in subjects previously treated with latanoprost. Kurtz, S; Mann, O, )	1.84
"Bimatoprost is a synthetic prostamide analog that is efficacious in the treatment of open-angle glaucoma, ocular hypertension and other forms of glaucoma. "	( Bimatoprost - a review. Edward, DP; Patil, AJ; Vajaranant, TS, 2009)	3.24
"Bimatoprost is a neutral lipid, a fatty acid amide that pharmacologically acts in both its paternal amide form and through its hydrolysis product (active free fatty acid of bimatoprost). "	( [Bimatoprost therapy in glaucoma]. Călugăru, D; Călugăru, M, 2009)	2.71
"Bimatoprost (Lumigan) is a synthetic prostamide that reduces intraocular pressure (IOP) by increasing the outflow of aqueous humour. "	( Bimatoprost: a review of its use in open-angle glaucoma and ocular hypertension. Curran, MP, 2009)	3.24
"Bimatoprost is a widely used ocular hypotensive agent to treat glaucoma. "	( Cellular basis for bimatoprost effects on human conventional outflow. Carling, RW; Cornell, CL; Fliri, H; Jolas, T; Martos, J; Pettit, SN; Piwnica, D; Stamer, WD; Wang, JW; Woodward, DF, 2010)	2.13
"Bimatoprost appears to be a valuable new agent for glaucoma therapy."	( An update on bimatoprost in glaucoma therapy. Cantor, LB, 2002)	1.41
"Bimatoprost is a synthetic prostamide, chemically related to prostamide F. "	( Granulomatous anterior uveitis associated with bimatoprost: a case report. Parentin, F, 2003)	2.02
"Bimatoprost is a pharmacologically unique and highly efficacious anti-glaucoma agent. "	( Update on the mechanism of action of bimatoprost: a review and discussion of new evidence. Krauss, AH; Woodward, DF, 2004)	2.04
"Bimatoprost is a structural analog of PGF2alpha-ethanolamide (prostamide F2alpha), which is formed from the endocannabinoid anandamide by a biosynthetic pathway involving cyclooxygenase-2 (COX-2)."	( Bimatoprost: a novel antiglaucoma agent. Chen, J; Krauss, AH; Liang, Y; Phelps, RL; Short, B; Weber, A; Wheeler, LA; Woodward, DF, 2004)	2.49
"Bimatoprost is a synthetic analog of prostaglandin F(2 alpha) ethanolamide (prostamide F(2 alpha)), and shares a pharmacological profile consistent with that of the prostamides. "	( Bimatoprost and prostaglandin F(2 alpha) selectively stimulate intracellular calcium signaling in different cat iris sphincter cells. Chen, J; Krauss, AH; Nieves, AL; Protzman, CE; Sachs, G; Scott, DF; Spada, CS; Wheeler, LA; Woodward, DF, 2005)	3.21
"Bimatoprost is an effective alternative to topical beta-blockers for the treatment of glaucoma and ocular hypertension."	( The efficacy of bimatoprost 0.03% monotherapy in patients previously using topical beta-blocker monotherapy for the treatment of glaucoma or ocular hypertension. Earl, ML; Quinones, R, )	1.2
"Bimatoprost is a safe and well-tolerated intraocular pressure (IOP) lowering drug that was approved in the United States in 2001 for the treatment of glaucoma and ocular hypertension. "	( Bimatoprost: mechanism of ocular surface hyperemia associated with topical therapy. Chen, J; Dinh, T; Holland, M; Lin, TH; Wheeler, LA; Woodward, DF; Yuan, YD, 2005)	3.21
"Bimatoprost (BMP), which is a highly effective ocular hypotensive agent, is a PGF(2)(alpha) analogue that inhibits both the PGD(2) 11-ketoreductase and PGH(2) 9,11-endoperoxide reductase activities of PGFS."	( Prostaglandin F2alpha formation from prostaglandin H2 by prostaglandin F synthase (PGFS): crystal structure of PGFS containing bimatoprost. Komoto, J; Takusagawa, F; Watanabe, K; Woodward, DF; Yamada, T, 2006)	1.26
"Bimatoprost (Lumigan) is a prostamide analogue used for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. "	( Bimatoprost: a pharmacoeconomic review of its use in open-angle glaucoma and ocular hypertension. Keam, SJ; Plosker, GL, 2006)	3.22
"Bimatoprost is a structural analog of prostaglandin F2 alpha-ethanolamide (PGF2a), a class of compounds that in systemic form has been associated with alterations in serum lipid levels."	( Decreased high-density lipoprotein serum levels associated with topical bimatoprost therapy. Steinhäuser, SL, 2006)	1.29
"Bimatoprost is a synthetic molecule that is structurally and pharmacologically similar to prostamide F(2), and appears to mimic the activity of the prostamides."	( Clinical pharmacology of bimatoprost. Cantor, LB, 2005)	1.35
"Bimatoprost (Lumigan) is a pharmacologically unique and highly efficacious ocular hypotensive agent. "	( The pharmacology of bimatoprost (Lumigan). Andrews, SW; Archeampong, A; Brar, B; Burk, RM; Chen, J; Chen, R; Garst, ME; Gil, DW; Kaplan, LJ; Kedzie, KM; Kharlamb, A; Krauss, AH; Lai, RK; Liang, Y; Ling, J; Madhu, C; Ni, J; Rix, P; Shi, L; Spada, CS; Tang-Liu, DD; Usansky, H; Usansky, J; Weber, A; Welty, D; Wheeler, LA; Woodward, DF; Yang, W, 2001)	2.08
"Bimatoprost is a new ocular hypotensive agent that lowers intraocular pressure (IOP) in normal, ocular hypertensive, and glaucomatous eyes. "	( Mechanism of action of bimatoprost (Lumigan). Brubaker, RF, 2001)	2.06

Excerpt	Reference	Relevance
"Bimatoprost has an IOP-lowering effect superior to that of latanoprost in glaucoma patients after switching from latanoprost. "	( Switching efficacy on intraocular pressure from latanoprost to bimatoprost in eyes with open angle glaucoma: implication to the changes of central corneal thickness. Sawada, A; Yamamoto, T, 2014)	2.08
"The bimatoprost implant has the potential to improve adherence and reduce treatment burden in glaucoma."	( Phase 3, Randomized, 20-Month Study of the Efficacy and Safety of Bimatoprost Implant in Patients with Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 2). Bacharach, J; Bejanian, M; Belalcázar, S; Chen, MY; Ferguson, G; Goodkin, ML; Guo, Q; Liu, J; Robinson, MR; Tatham, A; Thieme, H; Wirta, DL, 2021)	1.34
"Bimatoprost has been reported to treat primary open-angle glaucoma (POAG) effectively. "	( Efficacy of bimatoprost for the treatment of primary open-angle glaucoma: A protocol of systematic review and meta-analysis. Liu, HW; Lu, YT; Meng, Y; Ren, YB, 2020)	2.38
"The bimatoprost implant has potential to improve adherence and reduce treatment burden in glaucoma."	( Phase 3, Randomized, 20-Month Study of Bimatoprost Implant in Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 1). Bejanian, M; Coote, M; Goodkin, ML; Guo, Q; Kolko, M; Medeiros, FA; Robinson, MR; Walters, TR; Weinreb, RN; Zhang, J, 2020)	1.31
"Bimatoprost has known adnexal activity and was observed to increase nail growth at two clinical centers."	( The effect of cutaneous prostaglandin application on nail growth, nail brittleness, and intraocular pressure. Bueno, A; Palmer, DJ; Scheman, A; Tanna, AP, 2018)	1.92
"Bimatoprost 0.03% has enhanced eyelash prominence in clinical trials enrolling mostly Caucasian subjects. "	( Bimatoprost for eyelash growth in Japanese subjects: two multicenter controlled studies. Arase, S; Daniels, S; Harii, K; Tsuboi, R; VanDenburgh, A; Weng, E, 2014)	3.29
"Bimatoprost has an IOP-lowering effect superior to that of latanoprost in glaucoma patients after switching from latanoprost. "	( Switching efficacy on intraocular pressure from latanoprost to bimatoprost in eyes with open angle glaucoma: implication to the changes of central corneal thickness. Sawada, A; Yamamoto, T, 2014)	2.08
"Bimatoprost 0.03% has been shown to consistently reduce mean intraocular pressure (IOP) more than timolol 0.5% over 2 years. "	( Long-term efficacy and safety of bimatoprost for intraocular pressure lowering in glaucoma and ocular hypertension: year 4. Batoosingh, AL; Cohen, JS; Gross, RL; Liu, CC; Safyan, E; Williams, RD, 2008)	2.07
"Bimatoprost has also been suggested to lower intraocular pressure by behaving as a prodrug or, alternatively, by stimulating FP receptors directly."	( Update on the mechanism of action of bimatoprost: a review and discussion of new evidence. Krauss, AH; Woodward, DF, 2004)	1.32
"Bimatoprost 0.03% q.d. has also been shown to provide significantly better diurnal IOP control than latanoprost 0.005% q.d., probably the most efficacious topical medication currently available."	( Bimatoprost: a member of a new class of agents, the prostamides, for glaucoma management. Cantor, LB, 2001)	2.47
"Bimatoprost pharmacology has been extensively characterized by binding and functional studies at more than 100 drug targets, which comprise a diverse variety of receptors, ion channels, and transporters."	( The pharmacology of bimatoprost (Lumigan). Andrews, SW; Archeampong, A; Brar, B; Burk, RM; Chen, J; Chen, R; Garst, ME; Gil, DW; Kaplan, LJ; Kedzie, KM; Kharlamb, A; Krauss, AH; Lai, RK; Liang, Y; Ling, J; Madhu, C; Ni, J; Rix, P; Shi, L; Spada, CS; Tang-Liu, DD; Usansky, H; Usansky, J; Weber, A; Welty, D; Wheeler, LA; Woodward, DF; Yang, W, 2001)	1.36
"Bimatoprost has been reported to cause changes in the pigmentation of the periorbital skin, eyelashes and iris, and increase eyelash growth."	( Topical bimatoprost: a review of its use in open-angle glaucoma and ocular hypertension. Easthope, SE; Perry, CM, 2002)	1.47

Excerpt	Reference	Relevance
"Bimatoprost shows lower ocular tolerability with higher incidence of side effects such as conjunctival hyperemia."	( Efficacy and safety of prostaglandin analogues in primary open-angle glaucoma or ocular hypertension patients: A meta-analysis. Duan, X; Liu, K; Tang, W; Zhang, F, 2019)	1.24
"Bimatoprost provided lower mean pressures than latanoprost at every time point throughout the study and was statistically superior in achieving low target pressures."	( Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension. Chen, K; Gandolfi, S; Simmons, ST; Sturm, R; VanDenburgh, AM, )	1.15

Excerpt	Reference	Relevance
"4) Bimatoprost pretreatment did not attenuate PGF(2alpha)-induced Ca(2+) signals in Swiss 3T3 cells."	( Pharmacological characterization of a novel antiglaucoma agent, Bimatoprost (AGN 192024). Andrews, SW; Babusis, D; Bogardus, A; Burk, RM; Chen, J; Chen, R; Cherukury, M; Garst, ME; Gil, DW; Kedzie, KM; Kharlamb, A; Krauss, AH; Krauss, HA; Li, C; Liang, Y; Protzman, CE; Tang-Liu, DD; Welty, D; Wheeler, LA; Woodward, DF, 2003)	1.07
"Bimatoprost SR-treated eyes exhibited a selective, sustained dilation of aqueous outflow vessels that was not observed in sham-treated eyes."	( Bimatoprost sustained-release intracameral implant reduces episcleral venous pressure in dogs. Almazan, A; Burke, J; Hughes, P; Lee, SS; Li, H; Miller, PE; Orilla, W; Robinson, MR; Shen, J; Struble, C; Zhang, J, 2018)	2.64
"Bimatoprost-treated subjects had significantly greater increases in eyelash length, thickness, and darkness at the primary time point (month 4 in both studies; all P<0.001, study 1; P≤0.04, study 2)."	( Bimatoprost for eyelash growth in Japanese subjects: two multicenter controlled studies. Arase, S; Daniels, S; Harii, K; Tsuboi, R; VanDenburgh, A; Weng, E, 2014)	2.57
"Bimatoprost-treated eyes demonstrated less long-term fluctuation in IOP compared with latanoprost-treated eyes in this six-month study. "	( A comparison of long-term intraocular pressure fluctuation in patients treated with bimatoprost or latanoprost. Bernstein, P; Hollander, DA; Simmons, ST, 2008)	2.01
"Bimatoprost treatment was safe and well tolerated."	( Efficacy and safety of switching from topical latanoprost to bimatoprost in patients with normal-tension glaucoma. Baba, T; Fujimura, T; Hirooka, K; Mizote, M; Sato, S; Shiraga, F; Tenkumo, K; Ueda, H, 2011)	1.33
"Bimatoprost treatment was associated with a higher incidence of trace-to-mild conjunctival hyperemia than latanoprost."	( Effect of bimatoprost on patients with primary open-angle glaucoma or ocular hypertension who are nonresponders to latanoprost. Cimino, L; Gandolfi, SA, 2003)	1.44
"Bimatoprost treatment gave rise to a significantly lower mean IOP than timolol in all follow-up visits as from the first month (P<0.05). "	( A 6-month assessment of bimatoprost 0.03% vs timolol maleate 0.5%: hypotensive efficacy, macular thickness and flare in ocular-hypertensive and glaucoma patients. Garcia-Feijoo, J; Garcia-Sanchez, J; Larrosa, JM; Martin, E; Martinez-de-la-Casa, JM; Troyano, J, 2007)	2.09
"A bimatoprost 0.03% qd treatment arm was used for validation of the study."	( A double-masked, randomized, parallel comparison of a fixed combination of bimatoprost 0.03%/timolol 0.5% with non-fixed combination use in patients with glaucoma or ocular hypertension. Hommer, A, )	0.92
"Eyes treated with Bimatoprost SR exhibited a transient increase in mean EVP that peaked at day 8, followed by a decrease to levels below baseline."	( Bimatoprost sustained-release intracameral implant reduces episcleral venous pressure in dogs. Almazan, A; Burke, J; Hughes, P; Lee, SS; Li, H; Miller, PE; Orilla, W; Robinson, MR; Shen, J; Struble, C; Zhang, J, 2018)	2.25
"Treatment with bimatoprost 0.03% for at least 12 months is safe, and long-term use is associated with a high degree of satisfaction."	( A retrospective review and observational study of outcomes and safety of bimatoprost ophthalmic solution 0.03% for treating eyelash hypotrichosis. Campo, A; Caulkins, CA; Cox, SE; Davis, PG; Fagien, S; Gallagher, CJ; Yoelin, SG, 2014)	0.99
"Treatment with bimatoprost was costlier than brimonidine with daily costs/eye Rs."	( A pharmacoeconomic analysis to determine the relative cost-effectiveness of bimatoprost 0.03% eye drops and brimonidine 0.2% eye drops in patients of primary open-angle glaucoma/ocular hypertension. Gupta, A; Natt, NK; Singh, G; Singh, T, 2014)	0.97
"Treatment with bimatoprost produced a constant increase (1.85-8.83 μm) in CCT at all time-points of the study."	( The effect of prostaglandin analogues on central corneal thickness of patients with chronic open-angle glaucoma: a 2-year study on 129 eyes. Bafa, M; Georgopoulos, G; Mihas, C; Papaconstantinou, D; Stavrakas, P; Vergados, I, 2011)	0.71
"Treatment with bimatoprost was generally well tolerated, with conjunctival hyperaemia (mostly mild), growth of eyelashes and ocular pruritus being commonly reported."	( Bimatoprost: a review of its use in open-angle glaucoma and ocular hypertension. Curran, MP, 2009)	2.14
"Treatment with bimatoprost increases the percentage of eyelash follicles in anagen at any one time. "	( Enhancing the growth of natural eyelashes: the mechanism of bimatoprost-induced eyelash growth. Cohen, JL, 2010)	0.96

Excerpt	Reference	Relevance
" Both treatment regimens were safe and well tolerated, with no significant between-group differences in reports of specific adverse events."	( Efficacy and safety of bimatoprost in patients with elevated intraocular pressure: a 30-day comparison with latanoprost. Cooke, D; Dirks, M; DuBiner, H; Felix, C; Stewart, WC; VanDenburgh, AM, 2001)	0.62
"03% provided better diurnal IOP control than latanoprost and was safe and well tolerated in patients with ocular hypertension and glaucoma."	( Efficacy and safety of bimatoprost in patients with elevated intraocular pressure: a 30-day comparison with latanoprost. Cooke, D; Dirks, M; DuBiner, H; Felix, C; Stewart, WC; VanDenburgh, AM, 2001)	0.62
" Safety parameters included adverse events, hyperemia grading, laser flare meter analysis, heart rate, and blood pressure."	( Comparison of the ocular hypotensive lipid AGN 192024 with timolol: dosing, efficacy, and safety evaluation of a novel compound for glaucoma management. Batoosingh, A; Cheetham, J; David, R; Felix, C; Laibovitz, RA; Rosenthal, A; VanDenburgh, AM, 2001)	0.31
" All treatment regimens were safe and well tolerated, with no clinically significant effects on heart rate or blood pressure and no between-group differences in the incidence of adverse events."	( Comparison of the ocular hypotensive lipid AGN 192024 with timolol: dosing, efficacy, and safety evaluation of a novel compound for glaucoma management. Batoosingh, A; Cheetham, J; David, R; Felix, C; Laibovitz, RA; Rosenthal, A; VanDenburgh, AM, 2001)	0.31
" AGN 192024 was safe and well tolerated, and it provided superior ocular hypotensive efficacy and diurnal IOP control compared with timolol in patients with ocular hypertension and glaucoma."	( Comparison of the ocular hypotensive lipid AGN 192024 with timolol: dosing, efficacy, and safety evaluation of a novel compound for glaucoma management. Batoosingh, A; Cheetham, J; David, R; Felix, C; Laibovitz, RA; Rosenthal, A; VanDenburgh, AM, 2001)	0.31
" The impact on cellular viability and apoptosis in the same cell line was evaluated, to address the possible proinflammatory and/or toxic origin of the most frequent clinical impairments induced by prostanoids (i."	( In vitro study of inflammatory potential and toxicity profile of latanoprost, travoprost, and bimatoprost in conjunctiva-derived epithelial cells. Baudouin, C; Brignole-Baudouin, F; Guenoun, JM; Pauly, A; Rat, P; Warnet, JM, 2005)	0.55
"TNFalpha induced or stimulated expression of the three inflammatory markers, whereas the PGF2alpha, latanoprost, travoprost, and bimatoprost solutions did not induce an increase in these markers and even produced a marked reduction of ICAM-1 and PECAM-1 expression in those solutions most concentrated in BAC, thus suggesting a toxic phenomenon in cellular membranes induced by the preservative rather than the medication itself."	( In vitro study of inflammatory potential and toxicity profile of latanoprost, travoprost, and bimatoprost in conjunctiva-derived epithelial cells. Baudouin, C; Brignole-Baudouin, F; Guenoun, JM; Pauly, A; Rat, P; Warnet, JM, 2005)	0.75
" Bimatoprost was well-tolerated; the most commonly reported adverse event was conjunctival hyperaemia (19."	( Efficacy and safety of bimatoprost for the treatment of open-angle glaucoma and ocular hypertension: a three-month, open-label study in community-based practices in Thailand. Iemsomboon, W; Wanichwecha-Rungruang, B, 2005)	1.55
"We observed conjunctival hyperemia as the most common side effect of bimatoprost and travoprost."	( Comparison of ocular surface side effects of topical travoprost and bimatoprost. Alagöz, G; Bayer, A; Boran, C; Elçioğlu, M; Kükner, A; Serin, D, 2008)	0.82
" Safety measures included adverse events, biomicroscopy, ophthalmoscopy, visual acuity and visual field."	( Long-term efficacy and safety of bimatoprost for intraocular pressure lowering in glaucoma and ocular hypertension: year 4. Batoosingh, AL; Cohen, JS; Gross, RL; Liu, CC; Safyan, E; Williams, RD, 2008)	0.63
" No safety concerns developed during long-term bimatoprost treatment; two patients in the timolol treatment group discontinued after month 36 because of adverse events."	( Long-term efficacy and safety of bimatoprost for intraocular pressure lowering in glaucoma and ocular hypertension: year 4. Batoosingh, AL; Cohen, JS; Gross, RL; Liu, CC; Safyan, E; Williams, RD, 2008)	0.88
"To document patient/physician perceptions of adverse effects and their relationship to medication changes among patients prescribed prostaglandin analogs."	( The impact of ocular adverse effects in patients treated with topical prostaglandin analogs: changes in prescription patterns and patient persistence. Gelb, L; Hahn, SR; Kim, EE; Tan, H; Zimmerman, TJ, 2009)	0.35
" Frequency of adverse effects noted by physicians and associations with medication change decisions were examined in charted data."	( The impact of ocular adverse effects in patients treated with topical prostaglandin analogs: changes in prescription patterns and patient persistence. Gelb, L; Hahn, SR; Kim, EE; Tan, H; Zimmerman, TJ, 2009)	0.35
" Adverse effects were the second most common reasons noted by physicians for switching medications after lack of efficacy (19% vs."	( The impact of ocular adverse effects in patients treated with topical prostaglandin analogs: changes in prescription patterns and patient persistence. Gelb, L; Hahn, SR; Kim, EE; Tan, H; Zimmerman, TJ, 2009)	0.35
"Ocular adverse effects, particularly hyperemia, negatively affect patient continuation with therapy and switching."	( The impact of ocular adverse effects in patients treated with topical prostaglandin analogs: changes in prescription patterns and patient persistence. Gelb, L; Hahn, SR; Kim, EE; Tan, H; Zimmerman, TJ, 2009)	0.35
" Tolerability was measured using a 4-step scale (excellent, good, moderate, poor) and all adverse events were recorded."	( Efficacy, tolerability and safety of the fixed combination of bimatoprost 0.03% and timolol 0.5% in a broad patient population: multicenter, open-label observational study. Buchholz, P; Feuerhake, C; Kimmich, F, 2009)	0.59
" Few adverse events occurred during the treatment period."	( Efficacy, tolerability and safety of the fixed combination of bimatoprost 0.03% and timolol 0.5% in a broad patient population: multicenter, open-label observational study. Buchholz, P; Feuerhake, C; Kimmich, F, 2009)	0.59
"5% was effective, well tolerated, and safe in a broad patient population."	( Efficacy, tolerability and safety of the fixed combination of bimatoprost 0.03% and timolol 0.5% in a broad patient population: multicenter, open-label observational study. Buchholz, P; Feuerhake, C; Kimmich, F, 2009)	0.59
"Latanoprost, travoprost, and bimatoprost are prostaglandin or prostamide-type ocular hypotensive medications, all of which are effective and safe for lowering intraocular pressure (IOP)."	( Prostaglandin efficacy and safety study undertaken by race (the PRESSURE study). Ahmed, II; Birt, CM; Buys, YM; Trope, GE, 2010)	0.65
" Adverse events and intraocular pressure were assessed, and subjects completed health outcomes questionnaires."	( Safety, effectiveness, and subjective experience with topical bimatoprost 0.03% for eyelash growth. Earl, M; Walt, JG; Yoelin, S, 2010)	0.6
" No serious or unexpected adverse events were reported."	( Safety, effectiveness, and subjective experience with topical bimatoprost 0.03% for eyelash growth. Earl, M; Walt, JG; Yoelin, S, 2010)	0.6
"Bimatoprost was found safe for eyelid application and was associated with enhanced eyelash growth."	( Safety, effectiveness, and subjective experience with topical bimatoprost 0.03% for eyelash growth. Earl, M; Walt, JG; Yoelin, S, 2010)	2.04
" We present 2 cases of a newly described side effect of both these topical agents in terms of periorbital fat atrophy."	( Periorbital fat atrophy - an unfamiliar side effect of prostaglandin analogues. Ghazi-Nouri, S; Jayaprakasam, A, 2010)	0.36
" Bimatoprost treatment was safe and well tolerated."	( Efficacy and safety of switching from topical latanoprost to bimatoprost in patients with normal-tension glaucoma. Baba, T; Fujimura, T; Hirooka, K; Mizote, M; Sato, S; Shiraga, F; Tenkumo, K; Ueda, H, 2011)	1.52
" The gastro-intestinal effects are among the most reported adverse effects upon topical application of PGAs."	( Possible mechanism for the gastro-intestinal adverse effects upon topical application of Prostaglandin F₂α analogs. Cai, S; Li, X; Liu, X; Yan, N; Zhou, X, 2013)	0.39
" Mild ocular redness was the commonest side effect in both the groups but was not significant in either group."	( Comparison of the efficacy and safety of bimatoprost (0.03 %) and travoprost (0.004 %) in patients with primary open angle glaucoma. Chander, A; Kapoor, H; Thomas, S, )	0.4
"Both drugs lowered IOP effectively but bimatoprost showed a greater reduction in the mean IOP than did travoprost at 12 weeks and both are safe for ocular use."	( Comparison of the efficacy and safety of bimatoprost (0.03 %) and travoprost (0.004 %) in patients with primary open angle glaucoma. Chander, A; Kapoor, H; Thomas, S, )	0.67
" The safety outcome measures included the rate of medication-related symptoms, physical signs, reported adverse events, and the level of conjunctival hyperemia."	( Intraocular pressure-lowering efficacy and safety of bimatoprost 0.03% therapy for primary open-angle glaucoma and ocular hypertension patients in China. Fang, A; Hou, J; Ji, J; Liu, Q; Sun, X; Wang, K; Wu, L; Xu, L; Yao, K; Yuan, Z; Zhang, M; Zhao, J, 2014)	0.65
" The most common adverse event was conjunctival hyperemia, mainly of trace and mild intensity."	( Intraocular pressure-lowering efficacy and safety of bimatoprost 0.03% therapy for primary open-angle glaucoma and ocular hypertension patients in China. Fang, A; Hou, J; Ji, J; Liu, Q; Sun, X; Wang, K; Wu, L; Xu, L; Yao, K; Yuan, Z; Zhang, M; Zhao, J, 2014)	0.65
" Adverse events were collected and slit-lamp examinations were performed to assess safety."	( Safety and efficacy of bimatoprost/timolol fixed combination in Chinese patients with open-angle glaucoma or ocular hypertension. Chen, X; Dong, Y; Fang, A; Hu, Y; Ling, Z; Liu, D; Sun, W; Sun, X; Wang, Y; Xing, Y; Ye, J; Yin, Z; Zhang, M, 2014)	0.71
" Adverse events occurred in 26."	( Safety and efficacy of bimatoprost/timolol fixed combination in Chinese patients with open-angle glaucoma or ocular hypertension. Chen, X; Dong, Y; Fang, A; Hu, Y; Ling, Z; Liu, D; Sun, W; Sun, X; Wang, Y; Xing, Y; Ye, J; Yin, Z; Zhang, M, 2014)	0.71
" Charts were reviewed for medication usage characteristics and adverse events (AEs)."	( A retrospective review and observational study of outcomes and safety of bimatoprost ophthalmic solution 0.03% for treating eyelash hypotrichosis. Campo, A; Caulkins, CA; Cox, SE; Davis, PG; Fagien, S; Gallagher, CJ; Yoelin, SG, 2014)	0.63
" No drug-related serious adverse events were reported."	( Long-term safety and efficacy of bimatoprost solution 0·03% application to the eyelid margin for the treatment of idiopathic and chemotherapy-induced eyelash hypotrichosis: a randomized controlled trial. Ahluwalia, G; Beddingfield, FC; Glaser, DA; Griffiths, T; Hossain, P; Perkins, W; Weng, E, 2015)	0.7
" Adverse effects of the treatment were minimal and similar between the 2 groups."	( Efficacy and Safety of Bimatoprost 0.01% for the Treatment of Eyebrow Hypotrichosis: A Randomized, Double-Blind, Vehicle-Controlled Study. Chanasumon, N; Sriphojanart, T; Suchonwanit, P, 2019)	0.82
"03% bimatoprost are effective and safe for the treatment of eyebrow hypotrichosis."	( Comparison of the efficacy and safety of using 0.01% versus 0.03% bimatoprost for the treatment of eyebrow hypotrichosis: A randomized, double-blind, split-face, comparative study. Chanasumon, N; Harnchoowong, S; Sriphojanart, T; Suchonwanit, P, 2020)	1.35
" Safety measures included treatment-emergent adverse events (TEAEs) and corneal endothelial cell density (CECD)."	( Phase 3, Randomized, 20-Month Study of the Efficacy and Safety of Bimatoprost Implant in Patients with Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 2). Bacharach, J; Bejanian, M; Belalcázar, S; Chen, MY; Ferguson, G; Goodkin, ML; Guo, Q; Liu, J; Robinson, MR; Tatham, A; Thieme, H; Wirta, DL, 2021)	0.86

Excerpt	Reference	Relevance
"To assess the pharmacokinetic (PK)/pharmacodynamic (PD) relationship following intracameral Bimatoprost sustained-release (SR) implants (8, 15, 30, and 60 µg) in dogs to determine the optimal investigative dose in humans."	( Nonclinical Pharmacokinetic and Pharmacodynamic Assessment of Bimatoprost Following a Single Intracameral Injection of Sustained-Release Implants. Attar, M; Robinson, MR; Shen, J; Struble, C, 2020)	1.02

Excerpt	Reference	Relevance
"03% (PGF2α analogues) combined with narrowband ultraviolet B (NB-UVB) was reported to be an effective treatment for vitiligo."	( The efficacy of bimatoprost ophthalmic solution combined with NB-UVB phototherapy in non-segmental and segmental vitiligo: a single-blind randomized controlled study. Apinuntham, C; Chaiyabutr, C; Charoenpipatsin, N; Likittanasombat, S; Pruksaeakanan, C; Silpa-Archa, N; Wongpraparut, C, 2023)	1.26

Excerpt	Reference	Relevance
" These findings may be valuable in developing formulation strategies to optimize ocular bioavailability of topically administered ocular agents."	( Expression of multidrug resistance associated protein 5 (MRP5) on cornea and its role in drug efflux. Herndon, BL; Karla, PK; Mitra, A; Pal, D; Quinn, TL; Thomas, P, 2009)	0.35

Excerpt	Relevance	Reference
" Twice-daily dosing of bimatoprost also provided significantly greater mean reductions in IOP than timolol at most time points but was not as effective as once-daily dosing."	( Comparison of once- or twice-daily bimatoprost with twice-daily timolol in patients with elevated IOP : a 3-month clinical trial. Brandt, JD; Chen, K; VanDenburgh, AM; Whitcup, SM, 2001)	0.9
" BID dosing of bimatoprost also provided significantly greater mean IOP reductions than timolol at most timepoints, but was not as effective as QD dosing."	( Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressure. Brandt, J; Sherwood, M, 2001)	0.97
" The reduction in IOP was maintained throughout the 24-hour dosage interval."	( Topical bimatoprost: a review of its use in open-angle glaucoma and ocular hypertension. Easthope, SE; Perry, CM, 2002)	0.75
"We evaluated conjunctival hyperemia by a standard photographic measure at the slit lamp and by anterior segment photographs in healthy subjects after dosing for 5 days with latanoprost, bimatoprost, or travoprost."	( Conjunctival hyperemia in healthy subjects after short-term dosing with latanoprost, bimatoprost, and travoprost. Jackson, AL; Kolker, AE; Leech, J; Stewart, JA; Stewart, WC, 2003)	0.73
"A single centered, active-controlled, three-period crossover comparison that evaluated conjunctival and corneal punctate staining, by grade and individual stains, in healthy subjects after dosing for five days in one eye with latanoprost, bimatoprost, or travoprost."	( Corneal punctate staining with latanoprost, bimatoprost, and travoprost in healthy subjects. Jackson, AL; Jenkins, JN; Stewart, JA; Stewart, WC, 2003)	0.76
"33) or at 1 hour after dosing (latanoprost 23."	( Corneal punctate staining with latanoprost, bimatoprost, and travoprost in healthy subjects. Jackson, AL; Jenkins, JN; Stewart, JA; Stewart, WC, 2003)	0.58
" The following 5 different dosing protocols were studied: latanoprost with bimatoprost added, bimatoprost with latanoprost added, latanoprost with travoprost added, travoprost with latanoprost added, and latanoprost with a second dose of latanoprost added."	( Additivity of bimatoprost or travoprost to latanoprost in glaucomatous monkey eyes. Gagliuso, DJ; Mittag, TW; Podos, SM; Wang, RF, 2004)	0.91
"15% unoprostone isopropyl solution induced no significant ocular side effects in normal cats when dosed over a 10-day treatment period."	( The effects of bimatoprost and unoprostone isopropyl on the intraocular pressure of normal cats. Bartoe, JT; Brightman, AH; Davidson, HJ; Horton, MT; Jung, Y, )	0.48
" Acid metabolites were below the limit of quantitation in all samples taken 12 h after dosing and in all samples from placebo-treated patients."	( Levels of bimatoprost acid in the aqueous humour after bimatoprost treatment of patients with cataract. Acheampong, A; Cantor, LB; Catoira, Y; Cortes, A; Hoop, J; Valluri, S; Wheeler, LA; Woodward, DF; Wudunn, D; Yung, CW, 2007)	0.74
" Treatment with a fixed combination may, therefore, increase compliance as a result of simplifying the dosage regimen."	( Efficacy and safety of bimatoprost/timolol fixed combination in the treatment of glaucoma or ocular hypertension. Martinez, A; Sanchez, M, 2008)	0.66
" Patients randomised to bimatoprost twice daily had been switched to bimatoprost once daily dosing at month 24 (bimatoprost twice daily/once daily treatment group), and continued with once daily dosing through month 48 (n = 39)."	( Long-term efficacy and safety of bimatoprost for intraocular pressure lowering in glaucoma and ocular hypertension: year 4. Batoosingh, AL; Cohen, JS; Gross, RL; Liu, CC; Safyan, E; Williams, RD, 2008)	0.93
" Patients with an IOP of 22-29 mmHg inclusive at 8 AMwere randomized to either bimatoprost dosed each evening or DTFC twice-daily."	( A comparison of dorzolamide/timolol-fixed combination versus bimatoprost in patients with open-angle glaucoma who are poorly controlled on latanoprost. Nelson, LA; Sharpe, ED; Stewart, JA; Stewart, WC; Williams, RD, 2008)	0.81
"Both BTFC dosing regimens significantly reduce 24 h IOP in XFG compared with bimatoprost monotherapy."	( Twenty-four-hour intraocular pressure control with bimatoprost and the bimatoprost/timolol fixed combination administered in the morning, or evening in exfoliative glaucoma. Embeslidis, T; Georgiadou, I; Haidich, AB; Holló, G; Irkec, M; Konstas, AG; Melamed, S; Mikropoulos, D; Tsironi, S, 2010)	0.84
" After a 1 week run-in period with bimatoprost all patients were treated with bimatoprost dosed once in the morning for 1 month, after which dorzolamide was added twice daily for 2 months."	( The additive effect of dorzolamide hydrochloride (Trusopt) and a morning dose of bimatoprost (Lumigan) on intraocular pressure and retrobulbar blood flow in patients with primary open-angle glaucoma. Ehrlich, R; Fuksinska, B; Harris, A; Robaszkiewicz, J; Siemiatkowska, A; Siesky, B; Stankiewicz, A; Wierzbowska, J; Zegadlo, A, 2010)	0.86
"8 years, range 33-80; 68 women) with POAG received bimatoprost dosed once in the morning for 1 month, after which dorzolamide was added twice daily for 2 months."	( Intraocular pressure and ocular hemodynamics in patients with primary open-angle glaucoma treated with the combination of morning dosing of bimatoprost and dorzolamide hydrochloride. Ehrlich, R; Grabska-Liberek, I; Harris, A; Misiuk-Hojło, M; Mulak, M; Romanowska-Dixon, B; Sierdziński, J; Siesky, B; Stankiewicz, A; Szuścik, I; Wasyluk, J; Wierzbowska, J, 2011)	0.82
"UBM revealed cyclodialysis in the patient's affected eye after a single dosage of bimatoprost."	( A case hypersensitive to bimatoprost and dexamethasone. Li, X; Liu, G; Liu, X; Wang, Y; Xiang, H; Yu, W, 2011)	0.9
"Bimatoprost/Timolol Fixed Combination administered in Chinese patients with open-angle glaucoma or ocular hypertension was not inferior to concurrent dosing with the individual components."	( Safety and efficacy of bimatoprost/timolol fixed combination in Chinese patients with open-angle glaucoma or ocular hypertension. Chen, X; Dong, Y; Fang, A; Hu, Y; Ling, Z; Liu, D; Sun, W; Sun, X; Wang, Y; Xing, Y; Ye, J; Yin, Z; Zhang, M, 2014)	2.16
"To compare the dose-response profiles of bimatoprost sustained-release implant (Bimatoprost SR) and topical bimatoprost in lowering intraocular pressure (IOP) in normotensive beagle dogs."	( Dose-Response of Intracameral Bimatoprost Sustained-Release Implant and Topical Bimatoprost in Lowering Intraocular Pressure. Almazan, A; Dibas, M; Lee, SS; Robinson, MR, 2019)	1.07
"There is a limit beyond which increasing either the concentration of a prostaglandin analog (PGA) or its dosing frequency fails to produce increases in ocular hypotensive efficacy with topical dosing."	( Episcleral Venous Pressure and the Ocular Hypotensive Effects of Topical and Intracameral Prostaglandin Analogs. Lee, SS; Robinson, MR; Weinreb, RN, 2019)	0.51
" Several studies are underway to investigate mechanisms of action and to better understand safe and effective dosing of medications in this class."	( Intracameral sustained release bimatoprost implants (Durysta). Lin, MM; Sirinek, PE, 2022)	1.01
" Intraocular pressure (IOP), ophthalmic artery resistive index (OA-RI), and electroretinogram (ERG) data were collected prior to dosing and at different time points postdosing."	( NCX 470 Exerts Retinal Cell Protection and Enhances Ophthalmic Artery Blood Flow After Ischemia/Reperfusion Injury of Optic Nerve Head and Retina. Bastia, E; Brambilla, S; Galli, C; Impagnatiello, F; Lucarini, L; Marri, S; Masini, E; Provensi, G; Sgambellone, S; Villano, S, 2023)	0.91
"NCX 470 repeated ocular dosing ameliorates ocular hemodynamics and retinal cell dysfunction caused by ischemia/reperfusion via nitric oxide- and bimatoprost-mediated mechanisms."	( NCX 470 Exerts Retinal Cell Protection and Enhances Ophthalmic Artery Blood Flow After Ischemia/Reperfusion Injury of Optic Nerve Head and Retina. Bastia, E; Brambilla, S; Galli, C; Impagnatiello, F; Lucarini, L; Marri, S; Masini, E; Provensi, G; Sgambellone, S; Villano, S, 2023)	1.11

Role	Description
antiglaucoma drug	Any drug which can be used to prevent or alleviate glaucoma, a disease in which the optic nerve is damaged, resulting in progressive, irreversible loss of vision. It is often, though not always, associated with increased pressure of the fluid in the eye.
antihypertensive agent	Any drug used in the treatment of acute or chronic vascular hypertension regardless of pharmacological mechanism.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
monocarboxylic acid amide	A carboxamide derived from a monocarboxylic acid.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
ATP-binding cassette sub-family C member 3	Homo sapiens (human)	IC50 (µMol)	133.0000	0.6315	4.4531	9.3000	AID1473740
Multidrug resistance-associated protein 4	Homo sapiens (human)	IC50 (µMol)	133.0000	0.2000	5.6774	10.0000	AID1473741
Bile salt export pump	Homo sapiens (human)	IC50 (µMol)	40.4000	0.1100	7.1903	10.0000	AID1473738
Canalicular multispecific organic anion transporter 1	Homo sapiens (human)	IC50 (µMol)	133.0000	2.4100	6.3433	10.0000	AID1473739
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
xenobiotic metabolic process	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
bile acid and bile salt transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
leukotriene transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
monoatomic anion transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transport across blood-brain barrier	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
prostaglandin secretion	Multidrug resistance-associated protein 4	Homo sapiens (human)
cilium assembly	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet degranulation	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic metabolic process	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
bile acid and bile salt transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
cAMP transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
leukotriene transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
monoatomic anion transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
export across plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
transport across blood-brain barrier	Multidrug resistance-associated protein 4	Homo sapiens (human)
guanine nucleotide transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
fatty acid metabolic process	Bile salt export pump	Homo sapiens (human)
bile acid biosynthetic process	Bile salt export pump	Homo sapiens (human)
xenobiotic metabolic process	Bile salt export pump	Homo sapiens (human)
xenobiotic transmembrane transport	Bile salt export pump	Homo sapiens (human)
response to oxidative stress	Bile salt export pump	Homo sapiens (human)
bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
response to organic cyclic compound	Bile salt export pump	Homo sapiens (human)
bile acid and bile salt transport	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transport	Bile salt export pump	Homo sapiens (human)
protein ubiquitination	Bile salt export pump	Homo sapiens (human)
regulation of fatty acid beta-oxidation	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transport	Bile salt export pump	Homo sapiens (human)
bile acid signaling pathway	Bile salt export pump	Homo sapiens (human)
cholesterol homeostasis	Bile salt export pump	Homo sapiens (human)
response to estrogen	Bile salt export pump	Homo sapiens (human)
response to ethanol	Bile salt export pump	Homo sapiens (human)
xenobiotic export from cell	Bile salt export pump	Homo sapiens (human)
lipid homeostasis	Bile salt export pump	Homo sapiens (human)
phospholipid homeostasis	Bile salt export pump	Homo sapiens (human)
positive regulation of bile acid secretion	Bile salt export pump	Homo sapiens (human)
regulation of bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
transmembrane transport	Bile salt export pump	Homo sapiens (human)
xenobiotic metabolic process	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
negative regulation of gene expression	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bile acid and bile salt transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
heme catabolic process	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic export from cell	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transepithelial transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
leukotriene transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
monoatomic anion transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transport across blood-brain barrier	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transport across blood-brain barrier	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
ATP binding	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type xenobiotic transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type bile acid transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATP hydrolysis activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
icosanoid transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
guanine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
protein binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
purine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type bile acid transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
efflux transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP hydrolysis activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
protein binding	Bile salt export pump	Homo sapiens (human)
ATP binding	Bile salt export pump	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Bile salt export pump	Homo sapiens (human)
bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
ABC-type bile acid transporter activity	Bile salt export pump	Homo sapiens (human)
ATP hydrolysis activity	Bile salt export pump	Homo sapiens (human)
protein binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
organic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP hydrolysis activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basal plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basolateral plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
nucleolus	Multidrug resistance-associated protein 4	Homo sapiens (human)
Golgi apparatus	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
basolateral plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet dense granule membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
external side of apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
basolateral plasma membrane	Bile salt export pump	Homo sapiens (human)
Golgi membrane	Bile salt export pump	Homo sapiens (human)
endosome	Bile salt export pump	Homo sapiens (human)
plasma membrane	Bile salt export pump	Homo sapiens (human)
cell surface	Bile salt export pump	Homo sapiens (human)
apical plasma membrane	Bile salt export pump	Homo sapiens (human)
intercellular canaliculus	Bile salt export pump	Homo sapiens (human)
intracellular canaliculus	Bile salt export pump	Homo sapiens (human)
recycling endosome	Bile salt export pump	Homo sapiens (human)
recycling endosome membrane	Bile salt export pump	Homo sapiens (human)
extracellular exosome	Bile salt export pump	Homo sapiens (human)
membrane	Bile salt export pump	Homo sapiens (human)
plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
cell surface	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
intercellular canaliculus	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Assay ID	Title	Year	Journal	Article
AID625292	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1473738	Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1473741	Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID625282	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625288	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625281	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625286	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625280	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625289	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625279	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625284	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1473737	AUC in human administered intraocularly as 1 drop QD of 0.03% solution after 24 hrs	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID625285	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1473742	Drug concentration at steady state in human administered intraocularly as 1 drop QD of 0.03% solution after 24 hrs	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1473743	Ratio of drug concentration at steady state in human administered intraocularly as 1 drop QD of 0.03% solution after 24 hrs to IC50 for human BSEP overexpressed in Sf9 insect cells	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1473740	Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID625290	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625291	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1674156	Drug release in pH 7.2 simulated tear fluid measured at 240 hrs by HPLC method	2020	Journal of medicinal chemistry, 10-08, Volume: 63, Issue:19	Ocular Disease Therapeutics: Design and Delivery of Drugs for Diseases of the Eye.
AID625287	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625283	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1473739	Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1346394	Human FP receptor (Prostanoid receptors)	2003	The Journal of pharmacology and experimental therapeutics, May, Volume: 305, Issue:2	Pharmacological characterization of a novel antiglaucoma agent, Bimatoprost (AGN 192024).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	241 (44.38)	29.6817
2010's	226 (41.62)	24.3611
2020's	76 (14.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	184 (30.98%)	5.53%
Reviews	79 (13.30%)	6.00%
Case Studies	67 (11.28%)	4.05%
Observational	11 (1.85%)	0.25%
Other	253 (42.59%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (149)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in Patients With Open-Angle Glaucoma or Ocular Hypertension [NCT02507687]	Phase 3	240 participants (Actual)	Interventional	2015-08-27	Completed
Effects of Latanoprost, Bimatoprost and Travoprost in Patients With Latanoprost-resistant Glaucoma [NCT01361841]		141 participants (Anticipated)	Interventional	2009-01-31	Recruiting
Topical Bimatoprost for Chemical Blepharoplasty [NCT02830776]	Early Phase 1	15 participants (Actual)	Interventional	2016-11-30	Completed
Choroidal Thickness and Its Correlations With Ocular Parameters in Cases With Primary Open-angle Glaucoma [NCT03966560]	Phase 4	96 participants (Actual)	Interventional	2014-01-31	Completed
[NCT02505776]		1,699 participants (Actual)	Observational	2014-12-08	Completed
Effect of Bimatoprost (Lumigan) in Gel Suspension Applied to the Eyelashes on Eyelash Growth [NCT00773136]		21 participants (Actual)	Interventional	2008-02-29	Completed
A Randomised Control Study to Investigate if the Continuation of Prostaglandin Analogue Treatments in the Post-operative Phase of Glaucoma Patients Undergoing Cataract Surgery Increases the Incidence of Cystoid Macular Oedema. [NCT03292796]	Phase 2	56 participants (Actual)	Interventional	2016-12-07	Completed
An Extension Trial to Evaluate the Long-term Safety and Efficacy of Bimatoprost SR in Patients With Open Angle Glaucoma or Ocular Hypertension [NCT03891446]	Phase 3	600 participants (Anticipated)	Interventional	2019-03-27	Enrolling by invitation
A Phase IIa Randomized, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of Bimatoprost in the Treatment of Migraine [NCT03419715]	Phase 2	70 participants (Actual)	Interventional	2018-01-05	Active, not recruiting
Efficacy and Safety Assessment of T4030 Eye Drops Versus Ganfort® UD in Ocular Hypertensive or Glaucomatous Patients. [NCT04898387]	Phase 3	554 participants (Actual)	Interventional	2021-03-26	Completed
Efficacy and Safety Assessment of T4032 Versus Lumigan® in Ocular Hypertensive or Glaucomatous Patients [NCT03825380]	Phase 3	485 participants (Actual)	Interventional	2018-11-23	Completed
Stop Retinal Ganglion Cell Dysfunction Study [NCT02390284]	Phase 3	500 participants (Anticipated)	Interventional	2015-09-30	Active, not recruiting
Bimatoprost 0.03% Solution, NB-UVB and Fractional Carbon Dioxide Laser in Treatment of Generalized Vitiligo [NCT03487042]	Phase 4	40 participants (Anticipated)	Interventional	2018-05-31	Not yet recruiting
The Role of Bimatoprost Eyelash Gel in Chemotherapy-induced Madarosis: an Analysis of Efficacy and Safety [NCT01200251]	Phase 3	20 participants (Actual)	Interventional	2007-02-28	Completed
Efficacy and Safety of Topical Bimatoprost Solution 0.03% in Stable Vitiligo:A Preliminary Study [NCT01202513]	Phase 4	20 participants (Actual)	Interventional	2010-08-31	Withdrawn(stopped due to regulatory reasons)
A 2-year, Multicenter, Double-masked, Randomized, Parallel Study of the Safety of LUMIGAN® 0.1 mg/mL Compared With LUMIGAN® 0.3 mg/mL in Patients With Glaucoma or Ocular Hypertension [NCT01298700]	Phase 4	806 participants (Actual)	Interventional	2011-05-31	Completed
Efficacy and Safety of Adding the Brinzolamide/Timolol Maleate Fixed Combination (AZARGA®) to Ocular Hypertensive or Glaucoma Patients Uncontrolled on Prostaglandin Monotherapy [NCT01263444]	Phase 4	47 participants (Actual)	Interventional	2011-03-31	Completed
A 12-Month, Phase 4, Open Label, Multicenter, Trial to Assess the Efficacy and Safety of COMBIGAN® in Korean Patients With Primary Open Angle Glaucoma (POAG) and Normal Tension Glaucoma (NTG) [NCT02863705]	Phase 4	118 participants (Actual)	Interventional	2016-07-05	Completed
The Effects of Latanoprost, Bimatoprost and Travoprost on Periocular Skin Pigmentation [NCT00705757]	Phase 4	89 participants (Actual)	Interventional	2008-03-31	Completed
A Prospective, Multi-center, Randomized, Parallel-group, Controlled Study to Evaluate the Efficacy and Safety of OTX-TIC (Travoprost) Intracameral Implant in Subjects With Open-angle Glaucoma (OAG) or Ocular Hypertension (OHT) [NCT05335122]	Phase 2	105 participants (Anticipated)	Interventional	2022-03-16	Active, not recruiting
Phase 3 Study of Treatment of Soft Tissue Expansion and Exophthalmos in Inactive Thyroid Eye Disease Patients Using Drops of Prostaglandin Analogues. [NCT02155049]	Phase 3	10 participants (Actual)	Interventional	2014-11-30	Completed
A Phase 1B, Multicenter, Randomized, Double-masked, Controlled Study to Evaluate the Efficacy and Safety of a Fixed Combination Bimatoprost/Timolol Ocular Insert Compared to Its Individual Components With Crossover to Timolol 0.5% in Subjects With Open-an [NCT02742649]	Phase 1/Phase 2	55 participants (Actual)	Interventional	2016-04-30	Completed
A Prospective, Multicenter, Randomized, Masked, Controlled Study to Evaluate the Safety, Efficacy, and Dose-response of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Maleate Ophthalmic Solution, USP, 0.5% [NCT06120842]	Phase 1/Phase 2	140 participants (Anticipated)	Interventional	2023-10-13	Recruiting
Systemic Pharmacokinetic Study of T4032 (Unpreserved Bimatoprost 0.01%) Eye Gel Versus Lumigan® 0.01% Eye Drops in 40 Healthy Volunteers [NCT05729594]	Phase 1	40 participants (Actual)	Interventional	2023-02-27	Completed
Intraocular Pressure Reduction Efficacy of Rhopressa and Lumigan in Normal Tension Glaucoma [NCT04981886]	Phase 4	115 participants (Anticipated)	Interventional	2021-08-31	Not yet recruiting
Prostaglandin F2-alpha Eye Drops (Bimatoprost) in Thyroid Eye Disease: a Randomised Controlled Double Blind Crossover Trial [NCT02059655]	Phase 4	31 participants (Actual)	Interventional	2014-11-30	Completed
Comparison of the Effects of Bimatoprost and a Fixed Combination of Latanoprost and Timolol on 24-hour Blood and Ocular Perfusion Pressures [NCT02154217]	Phase 3	200 participants (Actual)	Interventional		Completed
[NCT01594970]	Phase 4	800 participants (Actual)	Interventional	2012-03-31	Completed
Aqueous Humor Dynamics of NCX 470 Ophthalmic Solution - A Double-Masked, Placebo-Controlled, Phase 3b Clinical Trial (Whistler) [NCT05938699]	Phase 2/Phase 3	20 participants (Anticipated)	Interventional	2023-12-01	Not yet recruiting
Efficacy Of The Bimatoprost/Timolol Fixed Combination In Patients Treated With Bimatoprost for Primary Open Angle Glaucoma, Exfoliation Glaucoma or Ocular Hypertension. [NCT00941096]	Phase 4	30 participants (Anticipated)	Interventional	2009-07-31	Completed
The Role of Bimatoprost in Graves' Periorbitopathy [NCT03708627]	Early Phase 1	3 participants (Anticipated)	Interventional	2017-11-01	Recruiting
An Open-label (Stage 1) and Randomized (Stage 2), 24 Month Study of Safety and Efficacy of Bimatoprost Drug Delivery System in Patients With Open-Angle Glaucoma or Ocular Hypertension [NCT01157364]	Phase 1/Phase 2	109 participants (Actual)	Interventional	2010-09-23	Completed
[NCT00440011]	Phase 4	266 participants (Actual)	Interventional	2006-08-31	Completed
[NCT01217606]	Phase 3	185 participants (Actual)	Interventional	2011-01-31	Completed
[NCT00651859]	Phase 2	111 participants (Actual)	Interventional	2002-11-30	Completed
Evaluation of Local Pharmacokinetics and Tolerability of Bimatoprost Applied Topically to the Scalp of Male Patients With Androgenetic Alopecia [NCT02848300]	Phase 1	11 participants (Actual)	Interventional	2016-07-31	Completed
Expanded Access to Bimatoprost [NCT05338606]		0 participants	Expanded Access		Available
[NCT00693420]	Phase 3	278 participants (Actual)	Interventional	2007-04-30	Completed
A Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in Patients With Open-Angle Glaucoma or Ocular Hypertension [NCT02636946]	Phase 3	144 participants (Actual)	Interventional	2016-02-24	Completed
Primary Glaucoma Treatment Trial in Kenya and South Africa - SLT vs. Medication [NCT02774811]		15 participants (Actual)	Interventional	2014-02-28	Terminated(stopped due to Unable to maintain a functional laser in the environment)
Efficacy of Topical Bimatoprost in Promoting Hair Growth in the Region of the Eyebrow and Eyelashes for Post-chemotherapy Patients Versus Normal Patients [NCT00999557]		0 participants (Actual)	Interventional	2016-01-31	Withdrawn(stopped due to Study was never opened)
Safety and Efficacy of Bimatoprost 0.03% Solution for the Treatment of Eyebrow Hypotrichosis: A Phase 4 Investigator Initiated Study [NCT01891487]	Phase 4	33 participants (Actual)	Interventional	2013-05-31	Completed
Intraocular Pressure and Tolerability Study of Preservative Free Bimatoprost 0.03% Unit Dose (BUDPF) or Preservative Free Latanoprost 0.005% Unit Dose (LUDPF) (Monoprost®) in Patients With Ocular Hypertension or Glaucoma: A Randomized, Single Masked, 3 Mo [NCT01975714]	Phase 4	67 participants (Actual)	Interventional	2013-10-31	Completed
Blood-aqueous Barrier Changes After the Use of Timolol and Prostaglandin Analogues Fixed Combination in Pseudophakic Patients With Primary Open Angle Glaucoma [NCT01978015]	Phase 4	69 participants (Actual)	Interventional	2011-10-31	Completed
Comparison of Bimatoprost and Lataprost in Patients With Chronic Angle-Closure Glaucoma: A Randomized Cross-Over Study [NCT00567788]		60 participants (Anticipated)	Interventional	2006-07-31	Active, not recruiting
[NCT01325337]	Phase 2	307 participants (Actual)	Interventional	2011-06-30	Completed
Evaluation of the Safety of GANFORT® (Bimatoprost 0.03% Plus Timolol 0.5%) Ophthalmic Solution in Chinese Patients With Open-angle Glaucoma or Ocular Hypertension [NCT02571712]	Phase 4	750 participants (Actual)	Interventional	2015-11-10	Completed
[NCT00652496]	Phase 2	249 participants (Actual)	Interventional	2005-01-31	Completed
Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Bimatoprost Topical Solution in the Treatment of Androgenetic Alopecia in Men [NCT02676310]	Phase 1	53 participants (Actual)	Interventional	2016-03-31	Terminated
Latisse(Bimatoprost .03% Opthalmic Solution) for the Treatment of Hypotrichosis of the Eyebrows: Latisse Versus Placebo [NCT01387906]	Phase 4	20 participants (Actual)	Interventional	2011-03-31	Completed
[NCT00332072]	Phase 3	541 participants (Actual)	Interventional	2001-08-31	Completed
[NCT00332540]	Phase 3	520 participants (Actual)	Interventional	2001-08-31	Completed
A Comparison of Latanoprost (Xalatan) With Travoprost (Travatan) and Bimatoprost (Lumigan) in Patients With Elevated Intraocular Pressure. A Twelve-week, Masked Evaluator, Phase IV, Multicenter Study in the United States. (Xalatan vs Travatan vs Lumigan). [NCT00847483]	Phase 4	375 participants (Actual)	Interventional	2002-01-31	Completed
Efficacy and Safety of Latanoprost (Xalatan) and Bimatoprost (Lumigan) Ophthalmic Solutions in Promoting Eyelash Growth in Patients With Alopecia Areata [NCT00187577]		14 participants (Actual)	Interventional	2005-06-30	Completed
The Effects of the Water Drinking Test on Intraocular Pressure of Glaucoma Patients Undergoing 24 Hour Continuous Monitoring With the SENSIMED Triggerfish [NCT01507584]		23 participants (Actual)	Interventional	2011-08-31	Completed
[NCT01833741]	Phase 4	1,137 participants (Actual)	Interventional	2009-12-31	Completed
Comparison of Bimatoprost 0.03% Monotherapy vs. Dual Therapy With Travoprost 0.004% and Timolol 0.5% in Patients With Glaucoma and Ocular Hypertension [NCT00348023]	Phase 4	0 participants	Interventional		Completed
A Multicenter Evaluation of Methods to Reduce Hyperemia Associated With Bimatoprost Therapy for Glaucoma or Ocular Hypertension [NCT00348062]	Phase 4	0 participants	Interventional		Completed
[NCT01325350]	Phase 2	306 participants (Actual)	Interventional	2011-06-30	Completed
A 3-month, 4-centre, Crossover, Double-masked Study Investigating the 24-hour Intraocular Pressure Control With the Bimatoprost/Timolol Fixed Combination Dosed Morning, or Evening in Subjects With Exfoliative Glaucoma [NCT00486486]	Phase 4	60 participants (Actual)	Interventional	2007-03-31	Completed
[NCT01241240]	Phase 3	192 participants (Actual)	Interventional	2011-03-31	Completed
[NCT00958035]	Phase 4	89 participants (Actual)	Interventional	2009-11-30	Completed
[NCT01016691]	Phase 2	47 participants (Actual)	Interventional	2009-10-31	Completed
Bioavailabilty of Bimatoprost Ophthalmic Solution in Human Aqueous. [NCT00355446]	Phase 4	48 participants	Interventional	2001-07-31	Completed
[NCT01853085]		1,830 participants (Actual)	Observational	2013-04-01	Completed
An Evaluation of Use of Topical Ocular Hypotensive Medication by Electronic Compliance Measures [NCT00329095]	Phase 4	60 participants	Interventional	2005-12-31	Completed
[NCT00332059]	Phase 3	445 participants (Actual)	Interventional	2003-05-31	Completed
[NCT00539526]	Phase 4	106 participants (Actual)	Interventional	2007-09-30	Completed
[NCT00541242]	Phase 4	586 participants (Actual)	Interventional	2007-12-31	Completed
[NCT00716742]		1,099 participants (Actual)	Observational	2004-09-30	Completed
[NCT01177098]	Phase 3	561 participants (Actual)	Interventional	2010-10-31	Completed
A Multicenter, Double-masked, Randomized, Parallel-group Study Assessing the Safety and Efficacy of Once-daily Application of Bimatoprost Solution 0.03% Compared to Vehicle to Treat Chemotherapy-induced Hypotrichosis of the Eyelashes in Japanese Subjects [NCT01391286]	Phase 3	36 participants (Actual)	Interventional	2011-07-01	Completed
A Phase 1/2 Study to Evaluate the Safety and Efficacy of AGN-193408 SR in Participants With Open-Angle Glaucoma or Ocular Hypertension [NCT04499248]	Phase 1/Phase 2	96 participants (Anticipated)	Interventional	2020-11-16	Recruiting
Bimatoprost/Timolol Versus Travoprost/Timolol Fixed Combinations in an Egyptian Population: A Hospital-Based Prospective Randomized Study [NCT01542710]		80 participants (Actual)	Interventional	2011-01-31	Completed
[NCT01589510]		419 participants (Actual)	Observational	2012-04-30	Completed
Topical Bimatoprost Effect on Androgen Dependent Hair Follicles [NCT02170662]	Phase 2	33 participants (Actual)	Interventional	2009-11-30	Completed
[NCT00273455]	Phase 4	34 participants	Interventional	2006-01-31	Completed
[NCT00300443]	Phase 2/Phase 3	561 participants (Actual)	Interventional	2005-12-31	Completed
Diurnal Curves With Bimatoprost 0.03% Versus Travoprost 0.004% [NCT00347802]	Phase 4	0 participants	Interventional		Completed
Efficacy of Bimatoprost 0.03% in Patients Who Are Low-Responders to Latanoprost [NCT00347841]	Phase 4	0 participants	Interventional		Completed
[NCT01064882]	Phase 2	104 participants (Actual)	Interventional	2010-03-31	Completed
The 24 Control of IOP in Ocular Hypertension: a Cross-over Study on Inflow Versus Outflow Drugs. [NCT01655758]	Phase 4	61 participants (Actual)	Interventional	2002-01-31	Completed
A Multicenter, Double-masked, Randomized, Parallel-group Study Assessing the Safety and Efficacy of Once-Daily Application of Bimatoprost Solution 0.03% Compared to Vehicle in Increasing Overall Eyelash Prominence in Japanese Subjects With Hypotrichosis o [NCT01391273]	Phase 3	173 participants (Actual)	Interventional	2011-07-01	Completed
[NCT01698554]	Phase 3	464 participants (Actual)	Interventional	2012-11-30	Completed
A Randomized ( 1:1), Double-Masked, Multi-Center, Two-Treatment, Single-Period, Parallel Design, Mutiple Dose Bioequivalence Study With Clinical End-Point of Bimatoprost Ophthalmic Solution 0.01% of Mankind Pharma Limited With LUMIGAN (Bimatoprost Ophthal [NCT04890106]	Phase 3	310 participants (Actual)	Interventional	2021-10-02	Completed
[NCT01170884]	Phase 4	121 participants (Actual)	Interventional	2009-12-31	Completed
[NCT01489670]		387 participants (Actual)	Observational	2011-09-30	Completed
[NCT01628588]		854 participants (Actual)	Observational	2010-03-31	Completed
[NCT01904721]	Phase 2	244 participants (Actual)	Interventional	2013-08-31	Completed
[NCT02061683]	Phase 4	263 participants (Actual)	Interventional	2010-04-19	Completed
[NCT01765764]	Phase 3	357 participants (Actual)	Interventional	2013-03-13	Completed
[NCT01830140]	Phase 3	466 participants (Actual)	Interventional	2013-07-31	Completed
[NCT01547598]	Phase 4	135 participants (Actual)	Interventional	2011-12-31	Completed
Efficacy of Combined CO2 Fractional Laser With Bimatoprost 0.03% in Treatment of Alopecia Areata [NCT05600673]	Phase 1/Phase 2	30 participants (Actual)	Interventional	2019-01-01	Completed
[NCT00809848]	Phase 1/Phase 2	172 participants (Actual)	Interventional	2009-02-28	Completed
24-Hour Intraocular Pressure Control Obtained With the Bimatoprost/Timolol Fixed Combination Compared With Latanoprost as First Choice Therapy in Subjects With Exfoliation Syndrome, or Exfoliative Glaucoma [NCT01448837]	Phase 4	37 participants (Actual)	Interventional	2010-04-30	Completed
[NCT01110499]	Phase 2	163 participants (Actual)	Interventional	2010-06-30	Completed
The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients. [NCT01927406]	Phase 4	0 participants (Actual)	Interventional	2014-06-30	Withdrawn(stopped due to Funding source unavailable)
[NCT01189279]	Phase 1	42 participants (Actual)	Interventional	2010-10-31	Completed
[NCT01243567]	Phase 4	81 participants (Actual)	Interventional	2010-06-01	Completed
[NCT01001195]	Phase 2	165 participants (Actual)	Interventional	2009-11-30	Completed
[NCT01525173]	Phase 4	137 participants (Actual)	Interventional	2012-01-31	Completed
[NCT01628601]		392 participants (Actual)	Observational	2010-05-31	Completed
[NCT01632423]		10,337 participants (Actual)	Observational	2010-02-28	Completed
[NCT01646151]		2,580 participants (Actual)	Observational	2012-05-31	Completed
Assessing the Efficacy and Tolerability of TRAVATAN® Solution Without BAK, Containing Polyquad® Preservative (Travoprost 0.004%) Versus LUMIGAN® 0.01% Solution With BAK (Bimatoprost 0.01%) in Treatment Naïve Patients With Ocular Hypertension or Open Angle [NCT01664039]	Phase 4	104 participants (Actual)	Interventional	2012-09-30	Completed
[NCT01023841]	Phase 4	71 participants (Actual)	Interventional	2010-06-01	Completed
[NCT01099774]	Phase 3	597 participants (Actual)	Interventional	2010-05-01	Completed
A Phase 3b Study to Evaluate the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension [NCT03850782]	Phase 3	515 participants (Actual)	Interventional	2019-02-28	Active, not recruiting
[NCT01253902]	Phase 4	164 participants (Actual)	Interventional	2010-12-31	Completed
24-hour IOP-lowering Effect of 0.01% Bimatoprost [NCT01271686]	Phase 4	16 participants (Actual)	Interventional	2011-01-31	Completed
A Randomized, Double-blind, Multiple Dose, Parallel-group, Two-arm, Multicenter, Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® (Bimatoprost Ophthalmic Solution) 0.01% in the Treatment of Subjects [NCT05401357]	Phase 3	168 participants (Anticipated)	Interventional	2022-06-29	Recruiting
A Phase 2 Prospective, Multicenter, Randomized, Double-masked, Controlled Study to Evaluate the Efficacy and Safety and Dose-response of the Bimatoprost Ocular Insert (2.2 mg, 13 mg) With and Without Concomitant Artificial Tears Compared to a Placebo Ocul [NCT02358369]	Phase 2	156 participants (Actual)	Interventional	2015-01-19	Completed
Preservative-free Fixed-dose Combination of Tafluprost 0.0015% / Timolol 0.5% in Patients With Open-angle Glaucoma or Ocular Hypertension: Clinical Effectiveness, Tolerability and Safety in a Real World Setting [NCT04828057]		50 participants (Actual)	Observational	2021-09-01	Completed
An Open-label Extension (OLE 2) Study to Evaluate the Safety of the 13 mg Bimatoprost Ocular Insert in Subjects With Open-angle Glaucoma or Ocular Hypertension Who Have Completed Study FSV5-004 [NCT02537015]	Phase 2	81 participants (Actual)	Interventional	2015-08-10	Completed
The Efficacy and Safety of Bimatoprost SR in Patients With Open-angle Glaucoma or Ocular Hypertension [NCT02250651]	Phase 3	528 participants (Actual)	Interventional	2014-12-15	Completed
A Proof of Concept, Split Study Measuring the Effectiveness of Topical ProstaglandinF2alpha, Microneedling and Excimer Laser in the Treatment of Vitiligo [NCT04738149]	Early Phase 1	4 participants (Actual)	Interventional	2021-11-02	Completed
[NCT02020512]	Phase 4	87 participants (Actual)	Interventional	2011-07-31	Completed
[NCT01291108]	Phase 2	125 participants (Actual)	Interventional	2011-04-30	Completed
Efficacy and Safety Assessment of T4032 (Unpreserved Bimatoprost 0.01%) Versus Lumigan® 0.01% in Ocular Hypertensive or Glaucomatous Patients [NCT05397600]	Phase 3	684 participants (Actual)	Interventional	2022-06-22	Active, not recruiting
Safety and Efficacy Assessment of Monoprost® in Comparison With Lumigan® 0.01% and Lumigan® 0.03% Unit Dose, in Patients With Primary Open Angle Glaucoma or Ocular Hypertension, Stabilized by Lumigan® 0.01% With Ocular Surface Intolerance [NCT02017327]	Phase 4	379 participants (Actual)	Interventional	2013-12-31	Completed
The Efficacy and Safety of Bimatoprost SR in Patients With Open-angle Glaucoma or Ocular Hypertension [NCT02247804]	Phase 3	594 participants (Actual)	Interventional	2014-12-15	Completed
[NCT02176356]	Phase 4	116 participants (Actual)	Interventional	2014-06-30	Completed
IOP and Tolerability Study of Preserved Bimatoprost 0.1% or Tafluprost Unit Dose Preservative Free 15microgram/ml, in Patients With OHT or Glaucoma Suitable for Prostaglandin Therapy [NCT02471105]	Phase 4	67 participants (Anticipated)	Interventional	2015-09-30	Recruiting
Evaluation of Laser-assisted Drug Delivery of Bimatoprost for the Treatment of Hypertrophic Scar Hypopigmentation: A Within Patient-Controlled Trial in Skin of Color [NCT06122090]	Phase 2	25 participants (Anticipated)	Interventional	2023-07-18	Recruiting
A PK Study to Assess the Relative Systemic Exposure to Bimatoprost and Bimatoprost Acid After Administration of a Single 13 mg Bimatoprost Ocular Insert for 1 Week in Medically Stable Adult Subjects With or Without Open-Angle Glaucoma or Ocular Hypertensi [NCT02444767]	Phase 1	11 participants (Actual)	Interventional	2015-03-31	Completed
A Multi-Center, Evaluator -Masked, Randomized, Parallel Group, Active Controlled, Comparative Study of SPARC's SDP-133 Once Daily Compared With Lumigan ® 0.01% (Bimatoprost Ophthalmic Solution) in Subjects With Open Angle Glaucoma or Ocular Hypertension [NCT03927443]	Phase 3	0 participants (Actual)	Interventional	2019-06-10	Withdrawn(stopped due to [Sponsors decision])
[NCT01229423]	Phase 4	62 participants (Actual)	Interventional	2009-11-30	Completed
[NCT01448525]	Phase 4	88 participants (Actual)	Interventional	2011-10-31	Completed
[NCT01623479]		585 participants (Actual)	Observational	2010-11-19	Completed
Additive Effect of Twice Daily Brinzolamide 1%/Brimonidine 0.2% Fixed Dose Combination as an Adjunctive Therapy to a Prostaglandin Analogue [NCT02419508]	Phase 4	290 participants (Actual)	Interventional	2015-08-07	Completed
[NCT01426113]	Phase 3	6 participants (Actual)	Interventional	2011-09-30	Terminated(stopped due to Study terminated due to corporate decision.)
[NCT01814761]		312 participants (Actual)	Observational	2013-05-31	Completed
[NCT00907426]	Phase 3	368 participants (Actual)	Interventional	2009-08-31	Completed
[NCT01863953]	Phase 2	112 participants (Actual)	Interventional	2013-06-30	Completed
[NCT01068964]		235 participants (Actual)	Interventional	2010-02-01	Completed
Comparison of Benzalkonium Chloride-containing Latanoprost and Preservative-free Bimatoprost on Ocular Surface Disease in Glaucoma Patients: a Prospective Randomised Study [NCT04896125]		300 participants (Anticipated)	Observational	2019-10-02	Recruiting
An Evaluation of the 24-Hour Intraocular Pressure(IOP)-Lowering Effect of Bimatoprost Sustained-Release(SR) in Participants With Open-Angle Glaucoma(OAG) or Ocular Hypertension(OHT) [NCT04285580]	Phase 3	37 participants (Actual)	Interventional	2020-06-11	Completed
[NCT01881126]	Phase 4	93 participants (Actual)	Interventional	2013-06-30	Completed
[NCT00538304]	Phase 2	222 participants (Actual)	Interventional	2007-11-30	Completed
A Multicenter, Open-label Study to Evaluate the Safety and Efficacy of Twice-daily 0.01% Bimatoprost/0.15% Brimonidine/0.5% Timolol Ophthalmic Solution (Triple Combination) in Patients in India, Who Have Glaucoma or Ocular Hypertension With Elevated IOP, [NCT01216943]	Phase 3	126 participants (Actual)	Interventional	2010-11-30	Completed
[NCT01976624]		756 participants (Actual)	Observational	2009-08-31	Completed
A Phase 2, Multicenter, Randomized, Subject- and Examiner-masked, Controlled Clinical Trial Designed to Evaluate the Safety and Effectiveness of the Bimatoprost Ocular Insert as Compared to Topical Timolol Solution (0.5%) in Patients With Glaucoma or Ocul [NCT01915940]	Phase 2	169 participants (Actual)	Interventional	2013-10-23	Completed
Assessment of Late Day IOP Control in Subjects With Open-Angle Glaucoma or Ocular Hypertension Treated With Travoprost 0.004% (TRAVATAN® Z) or Bimatoprost 0.01% (LUMIGAN®) [NCT01464424]	Phase 4	84 participants (Actual)	Interventional	2011-10-31	Completed
[NCT01568008]		933 participants (Actual)	Observational	2011-10-31	Completed
[NCT01999348]		1,553 participants (Actual)	Observational	2013-11-25	Completed
[NCT02097719]	Phase 4	100 participants (Actual)	Interventional	2014-05-31	Completed
Cutaneous Prostaglandin Application: Nail Growth, Nail Brittleness, and Eye Pressure [NCT02448043]		45 participants (Actual)	Interventional	2015-06-04	Completed
An Open-Label Extension (OLE) Study to Evaluate the Safety of the ForSight VISION5 Product in Subjects With Open-Angle Glaucoma or Ocular Hypertension Who Have Completed Study FSV5-002 [NCT02143843]	Phase 2	75 participants (Actual)	Interventional	2014-06-05	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00440011 (2) [back to overview]	Tolerability - Conjunctival Hyperemia
NCT00440011 (2) [back to overview]	Intraocular Pressure (IOP)
NCT00538304 (6) [back to overview]	Change From Baseline in Mean Peak Macroscopic Conjunctival Hyperemia at Month 1
NCT00538304 (6) [back to overview]	Percentage of Patients With an Increase in Macroscopic Conjunctival Hyperemia in Either Eye at Month 1
NCT00538304 (6) [back to overview]	Percentage of Physicians Who Were Very or Extremely Willing to Continue Patient on Drug, if Drug Were Marketed at Month 1
NCT00538304 (6) [back to overview]	Change From Baseline in Mean Intraocular Pressure (IOP) at Month 1
NCT00538304 (6) [back to overview]	Percentage of Patients Who Were Very or Extremely Willing to Use This Glaucoma Medication at Month 1
NCT00538304 (6) [back to overview]	Percentage of Patients Who Reported No Change in the Appearance of Their Eyes Since the Beginning of the Study at Month 1
NCT00539526 (3) [back to overview]	Change From Baseline in Corneal Staining With Fluorescein at Month 3
NCT00539526 (3) [back to overview]	Change From Baseline in Mean Conjunctival Hyperemia Scores at Month 3
NCT00539526 (3) [back to overview]	Change From Baseline in Tear Break-Up Time (TBUT) at Month 3
NCT00541242 (2) [back to overview]	Change From Baseline in Mean Diurnal Intraocular Pressure (IOP) at Week 18
NCT00541242 (2) [back to overview]	Change From Baseline in Mean Diurnal Intraocular Pressure (IOP) at Week 12
NCT00693420 (10) [back to overview]	Patient Reported Outcome: Overall Satisfaction With Eyelashes (Single Item) in Terms of Change From Baseline to Week 16
NCT00693420 (10) [back to overview]	Percentage of Participants Experiencing at Least a 1-grade Increase on the Global Eyelash Assessment (GEA) Scale From Baseline to Week 16
NCT00693420 (10) [back to overview]	Upper Eyelash Darkness as Measured by Digital Image Analysis in Terms of Change From Baseline to Week 16
NCT00693420 (10) [back to overview]	Upper Eyelash Length as Measured by Digital Image Analysis in Terms of Change From Baseline to Week 16
NCT00693420 (10) [back to overview]	Upper Eyelash Thickness as Measured by Digital Image Analysis in Terms of Change From Baseline to Week 16
NCT00693420 (10) [back to overview]	Percentage of Participants Experiencing at Least a 1-grade Increase on the Global Eyelash Assessment (GEA) Scale From Baseline to Week 20 (Post-treatment)
NCT00693420 (10) [back to overview]	Patient Reported Outcome: Overall Satisfaction With Eyelashes (Single Item) in Terms of Change From Baseline to Week 20 (Post-treatment)
NCT00693420 (10) [back to overview]	Upper Eyelash Darkness as Measured by Digital Image Analysis in Terms of Change From Baseline to Week 20 (Post-treatment)
NCT00693420 (10) [back to overview]	Upper Eyelash Length as Measured by Digital Image Analysis in Terms of Change From Baseline to Week 20 (Post-treatment)
NCT00693420 (10) [back to overview]	Upper Eyelash Thickness as Measured by Digital Image Analysis in Terms of Change From Baseline to Week 20 (Post-treatment)
NCT00705757 (1) [back to overview]	The Extent of Latanoprost, Bimatoprost and Travoprost Induced Periocular Skin Hyperpigmentation Over a One Year Time Course in Newly Diagnosed Primary Open Angle and Ocular Hypertension Patients.
NCT00716742 (1) [back to overview]	Change From Baseline in Bilateral Intraocular Pressure (IOP) at One Year
NCT00773136 (1) [back to overview]	Efficacy of Bimatoprost in Lengthening of Eyelashes
NCT00809848 (2) [back to overview]	Change From Baseline in Average Eye Intraocular Pressure (IOP)
NCT00809848 (2) [back to overview]	Percentage of Patients With ≥ 20% Reduction From Baseline in Diurnal IOP
NCT00907426 (5) [back to overview]	Percentage of Treatment Responders at Month 4
NCT00907426 (5) [back to overview]	Change From Baseline in Average Progressive Upper Eyelash Thickness at Month 4
NCT00907426 (5) [back to overview]	Percentage of Subjects With at Least a 1-Grade Improvement in Global Eyelash Assessment (GEA) Score at Month 4
NCT00907426 (5) [back to overview]	Change From Baseline in Upper Eyelash Length at Month 4
NCT00907426 (5) [back to overview]	Change From Baseline in Upper Eyelash Darkness at Month 4
NCT00958035 (1) [back to overview]	Percentage of Treatment Responders in Overall Eyelash Prominence at Month 4
NCT01001195 (1) [back to overview]	Change From Baseline in Average Eye Intraocular Pressure (IOP)
NCT01016691 (1) [back to overview]	Mean Change in Intraocular Pressure at Day 1
NCT01023841 (5) [back to overview]	Percentage of Participants With at Least a 1-Grade Improvement From Baseline in the Global Eyebrow Assessment (GEA) Score
NCT01023841 (5) [back to overview]	Percentage of Participants With Adverse Events
NCT01023841 (5) [back to overview]	Change From Baseline Upper Eyelash Length as Measured by Digital Image Analysis (DIA)
NCT01023841 (5) [back to overview]	Change From Baseline in Upper Eyelash Thickness as Measured by DIA
NCT01023841 (5) [back to overview]	Change From Baseline in Upper Eyelash Darkness as Measured by DIA
NCT01064882 (7) [back to overview]	Treatment Satisfaction Questionnaire Score at Month 3
NCT01064882 (7) [back to overview]	Change From Baseline in Upper Eyelash Darkness (in Intensity Units) at Month 3
NCT01064882 (7) [back to overview]	Change From Baseline in Upper Eyelash Thickness at Month 3
NCT01064882 (7) [back to overview]	Change From Baseline in the Confidence, Attractiveness, and Professionalism (CAP) Domain Scores at Month 3
NCT01064882 (7) [back to overview]	Change From Baseline in Overall Eyelash Satisfaction at Month 3
NCT01064882 (7) [back to overview]	Change From Baseline in Eyelash Length at Month 3
NCT01064882 (7) [back to overview]	Percentage of Subjects With a Clinical Response in Overall Eyelash Prominence on the Global Eyelash Assessment (GEA) at Month 3
NCT01068964 (1) [back to overview]	The Difference of Change From Baseline of Mean Diurnal Intraocular Pressure (IOP) Between the Two Treatment Groups at Week 4
NCT01099774 (4) [back to overview]	Average Eye IOP at Week 6
NCT01099774 (4) [back to overview]	Change From Baseline in Worse Eye Intraocular Pressure (IOP) at Week 12
NCT01099774 (4) [back to overview]	Average Eye IOP at Week 12
NCT01099774 (4) [back to overview]	Average Eye IOP at Week 2
NCT01110499 (2) [back to overview]	Part 2: Change From Baseline in Average Eye Intraocular Pressure (IOP)
NCT01110499 (2) [back to overview]	Part 1: Change From Baseline in Intraocular Pressure (IOP)
NCT01157364 (4) [back to overview]	Time to Rescue Treatment or Re-Treatment in the Study Eye
NCT01157364 (4) [back to overview]	Change From Baseline in Time-Matched Intraocular Pressure (IOP) in the Study Eye
NCT01157364 (4) [back to overview]	Mean Diurnal IOP in the Study Eye
NCT01157364 (4) [back to overview]	Time-Matched Intraocular Pressure (IOP) in the Study Eye
NCT01170884 (1) [back to overview]	Mean Diurnal Intraocular Pressure (IOP) at Week 12
NCT01177098 (6) [back to overview]	Average Eye Intraocular Pressure (IOP) at Each Hour Evaluated at Week 12
NCT01177098 (6) [back to overview]	Change From Baseline in Worse Eye IOP at Each Hour Evaluated at Week 12
NCT01177098 (6) [back to overview]	Change From Baseline in Average Eye IOP at Each Hour Evaluated at Week 12
NCT01177098 (6) [back to overview]	Average Eye Intraocular Pressure (IOP) at Each Hour Evaluated at Week 6
NCT01177098 (6) [back to overview]	Average Eye Intraocular Pressure (IOP) at Each Hour Evaluated at Week 2
NCT01177098 (6) [back to overview]	Change From Baseline in Worse Eye Intraocular Pressure (IOP) at Each Hour Evaluated at Week 12
NCT01189279 (5) [back to overview]	Maximum Plasma Level (Cmax) Following Multiple Doses of Bimatoprost
NCT01189279 (5) [back to overview]	Percentage of Patients With Clinically Significant Electrocardiogram (ECG) Findings
NCT01189279 (5) [back to overview]	Number of Patients With an at Least 1-Grade Severity Increase in Local Scalp Tolerability by Dermatologist Assessment
NCT01189279 (5) [back to overview]	Number of Patients With an at Least 1-Grade Severity Increase in Local Scalp Tolerability by Patient Assessment
NCT01189279 (5) [back to overview]	Maximum Plasma Level (Cmax) Following a Single Dose of Bimatoprost
NCT01216943 (1) [back to overview]	Change From Baseline in Mean Diurnal Intraocular Pressure (IOP) in the Study Eye
NCT01217606 (3) [back to overview]	Change From Baseline in Mean Worse Eye Intraocular Pressure (IOP) Analyzed by Two-Sample T-Test
NCT01217606 (3) [back to overview]	Change From Baseline in Mean Worse Eye Intraocular Pressure (IOP) Analyzed by Analysis of Covariance (ANCOVA)
NCT01217606 (3) [back to overview]	Change From Baseline in Mean Worse Eye Intraocular Pressure (IOP) Analyzed by Mixed-Effect Model for Repeated Measure
NCT01229423 (6) [back to overview]	Change From Baseline in Eyelash Intensity (Darkness) at Week 20
NCT01229423 (6) [back to overview]	Percentage of Subjects With an Improvement of at Least 1-Point in Global Eyelash Assessment (GEA) Score at Week 20
NCT01229423 (6) [back to overview]	Percentage of Subjects With an Improvement in Satisfaction With Overall Eyelash Prominence at Week 20
NCT01229423 (6) [back to overview]	Percentage of Subjects Satisfied With Treatment at Week 20
NCT01229423 (6) [back to overview]	Change From Baseline in Eyelash Thickness at Week 20
NCT01229423 (6) [back to overview]	Change From Baseline in Eyelash Length at Week 20
NCT01241240 (3) [back to overview]	Change From Baseline in Mean Worse Eye Intraocular Pressure (IOP) at Week 12
NCT01241240 (3) [back to overview]	Change From Baseline in Mean Worse Eye IOP
NCT01241240 (3) [back to overview]	Mean Worse Eye IOP
NCT01243567 (5) [back to overview]	Absolute Difference Between Patient's Lowest IOP Reading at Baseline (Day 0) and the Corresponding IOP Reading
NCT01243567 (5) [back to overview]	Change From Baseline in Average Intraocular Pressure (IOP)
NCT01243567 (5) [back to overview]	Absolute Difference Between Patient's Highest IOP Reading at Baseline (Day 0) and the Corresponding IOP Reading
NCT01243567 (5) [back to overview]	Change From Baseline IOP
NCT01243567 (5) [back to overview]	Percentage of Patients Reaching a Predefined Target Pressure Threshold
NCT01253902 (3) [back to overview]	Mean Corneal Staining With Fluorescein at Week 12
NCT01253902 (3) [back to overview]	Mean Conjunctival Hyperemia at Week 12
NCT01253902 (3) [back to overview]	Mean Tear Break Up Time (TBUT) at Week 12
NCT01263444 (4) [back to overview]	Mean Change From Baseline in IOP Per Prostaglandin Group at Week 12
NCT01263444 (4) [back to overview]	Percentage of Patients Reaching the Target IOP (≤ 18 mmHg)
NCT01263444 (4) [back to overview]	Mean Change From Baseline in IOP at Week 4
NCT01263444 (4) [back to overview]	Mean Change From Baseline in Intraocular Pressure (IOP) at Week 12
NCT01271686 (1) [back to overview]	Nocturnal Intraocular Pressure (IOP) Change
NCT01291108 (2) [back to overview]	Change From Baseline in Average Eye IOP
NCT01291108 (2) [back to overview]	Change From Baseline in Worse Eye IOP
NCT01298700 (2) [back to overview]	Percentage of Participants Reporting One or More Treatment-Related Ocular Surface Adverse Events
NCT01298700 (2) [back to overview]	"Percentage of Participants Reporting One or More Treatment-Related Ocular Surface Adverse Events Excluding Conjunctival Hyperemia"
NCT01325337 (6) [back to overview]	Percentage of Participants in Each Response Category of the Investigator Global Assessment (IGA) Score
NCT01325337 (6) [back to overview]	Percentage of Participants in Each Response Category of the Subject Self Assessment in Alopecia (SSA) Score
NCT01325337 (6) [back to overview]	Percentage of Participants in Each Response Category of the Global Panel Review (GPR) Score
NCT01325337 (6) [back to overview]	Change From Baseline in Target Area Hair Width (TAHW)
NCT01325337 (6) [back to overview]	Change From Baseline in Target Area Hair Darkness (TAHD)
NCT01325337 (6) [back to overview]	Change From Baseline in Target Area Hair Count (TAHC)
NCT01325350 (6) [back to overview]	Percentage of Participants in Each Response Category of the Subject Self Assessment in Alopecia (SSA) Score
NCT01325350 (6) [back to overview]	Percentage of Participants in Each Response Category of the Investigator Global Assessment (IGA) Score
NCT01325350 (6) [back to overview]	Percentage of Participants in Each Response Category of the Global Panel Review (GPR) Score
NCT01325350 (6) [back to overview]	Change From Baseline in Target Area Hair Width (TAHW)
NCT01325350 (6) [back to overview]	Change From Baseline in Target Area Hair Darkness (TAHD)
NCT01325350 (6) [back to overview]	Change From Baseline in Target Area Hair Count (TAHC)
NCT01391273 (4) [back to overview]	Change From Baseline in Eyelash Thickness as Measured by DIA
NCT01391273 (4) [back to overview]	Change From Baseline in Eyelash Length as Measured by Digital Image Analysis (DIA)
NCT01391273 (4) [back to overview]	Percentage of Participants With at Least a 1-Grade Increase in Overall Eyelash Prominence Using the Global Eyelash Assessment Scale (GEA)
NCT01391273 (4) [back to overview]	Change From Baseline in Eyelash Darkness as Measured by DIA
NCT01391286 (4) [back to overview]	Percentage of Participants With at Least a 1-Grade Increase in Overall Eyelash Prominence Using the Global Eyelash Assessment Scale (GEA)
NCT01391286 (4) [back to overview]	Change From Baseline in Eyelash Length as Measured by Digital Image Analysis (DIA)
NCT01391286 (4) [back to overview]	Change From Baseline in Eyelash Thickness as Measured by DIA
NCT01391286 (4) [back to overview]	Change From Baseline in Eyelash Darkness as Measured by DIA
NCT01448525 (2) [back to overview]	Percentage of Participants With at Least a 1-Grade Increase in the Global Eyelash Assessment (GEA) Score
NCT01448525 (2) [back to overview]	Percentage of Participants Who Are Satisfied or Very Satisfied With Their Eyelashes Overall
NCT01464424 (2) [back to overview]	Mean IOP at Each After Office Hour Evaluation Timepoint
NCT01464424 (2) [back to overview]	Overall Mean Intraocular Pressure (IOP)
NCT01489670 (7) [back to overview]	Physician Reported Reasons for Early Discontinuation of Treatment
NCT01489670 (7) [back to overview]	Intraocular Pressure (IOP) at Baseline
NCT01489670 (7) [back to overview]	Number of Patients Continuing Treatment After 12 Weeks
NCT01489670 (7) [back to overview]	Intraocular Pressure (IOP) at Week 12
NCT01489670 (7) [back to overview]	Patient Evaluation of Tolerability of Treatment Using a 4-Point Scale
NCT01489670 (7) [back to overview]	Physician Evaluation of Efficacy Using a 5-Point Scale
NCT01489670 (7) [back to overview]	Physician Evaluation of Tolerability of Treatment
NCT01525173 (1) [back to overview]	Change From Baseline in Mean Diurnal Intraocular Pressure (IOP)
NCT01547598 (5) [back to overview]	Percentage of Participants With ≥15% Reduction in Mean Diurnal IOP From Baseline
NCT01547598 (5) [back to overview]	Change From Baseline in Mean IOP at Week 6
NCT01547598 (5) [back to overview]	Change From Baseline in Mean IOP at Week 12
NCT01547598 (5) [back to overview]	Percentage of Participants With Mean Diurnal IOP Less Than 18 mmHg
NCT01547598 (5) [back to overview]	Mean Diurnal Intraocular Pressure (IOP)
NCT01568008 (6) [back to overview]	Physician Reported Reasons for Treatment Discontinuation
NCT01568008 (6) [back to overview]	Number of Patients Continuing Treatment After 12 Weeks
NCT01568008 (6) [back to overview]	Intraocular Pressure (IOP) at Baseline
NCT01568008 (6) [back to overview]	Physician Assessment of Treatment Tolerability Using a 4-Point Scale
NCT01568008 (6) [back to overview]	Intraocular Pressure (IOP) at Week 12
NCT01568008 (6) [back to overview]	Patient Assessment of Treatment Tolerability Using a 4-Point Scale
NCT01589510 (8) [back to overview]	Patient Assessment of Tolerability on a 4-Point Scale
NCT01589510 (8) [back to overview]	IOP at Week 14
NCT01589510 (8) [back to overview]	Percentage of Patients Who Discontinue Lumigan® 0.01% Prior to 14 Weeks of Treatment
NCT01589510 (8) [back to overview]	Intraocular Pressure (IOP) at Baseline
NCT01589510 (8) [back to overview]	Physician Evaluation of IOP Lowering in the Study Eye(s)
NCT01589510 (8) [back to overview]	Percentage of Patients Who Continue Lumigan® 0.01% Treatment
NCT01589510 (8) [back to overview]	Physician Assessment of Tolerability on a 4-Point Scale
NCT01589510 (8) [back to overview]	Physician Assessment of Patient Compliance Compared to Previous Therapy
NCT01594970 (4) [back to overview]	Change From Baseline in Intraocular Pressure (IOP)
NCT01594970 (4) [back to overview]	Overall Percent Change From Baseline in IOP
NCT01594970 (4) [back to overview]	Severity of Ocular Hyperemia in the Study Eye on a 5-Point Scale
NCT01594970 (4) [back to overview]	Change From Baseline in Hyperemia Severity in the Study Eye
NCT01623479 (3) [back to overview]	Number of Applications of Latisse® Per Week
NCT01623479 (3) [back to overview]	Percentage of Subjects Satisfied With Latisse®
NCT01623479 (3) [back to overview]	Percentage of Subjects Satisfied Wtih Their Eyelashes
NCT01628588 (5) [back to overview]	Patient Assessment of Tolerability Using a 4-Point Scale
NCT01628588 (5) [back to overview]	Change From Baseline in Intraocular Pressure (IOP)
NCT01628588 (5) [back to overview]	Physician Assessment of Tolerability Using a 4-Point Scale
NCT01628588 (5) [back to overview]	Patients Who Will Continue Use of Lumigan® After 14 Weeks
NCT01628588 (5) [back to overview]	Patients Who Discontinued Use of Lumigan® Prior to 14 Weeks
NCT01628601 (5) [back to overview]	Physician Assessment of Tolerability Using a 4-Point Scale
NCT01628601 (5) [back to overview]	Physician Assessment of Adherence to GANfort®
NCT01628601 (5) [back to overview]	Change From Baseline in Intraocular Pressure (IOP)
NCT01628601 (5) [back to overview]	Patients Continuing With GANfort® After 18 Weeks
NCT01628601 (5) [back to overview]	Patient Assessment of Tolerability Using a 4-Point Scale
NCT01632423 (5) [back to overview]	Physician Assessment of Tolerability Using a 4-Point Scale
NCT01632423 (5) [back to overview]	Patients Who Will Continue Use of Lumigan® After 14 Weeks
NCT01632423 (5) [back to overview]	Patients Who Discontinued Use of Lumigan® Prior to 14 Weeks
NCT01632423 (5) [back to overview]	Patient Assessment of Tolerability Using a 4-Point Scale
NCT01632423 (5) [back to overview]	Change From Baseline in Intraocular Pressure (IOP)
NCT01646151 (8) [back to overview]	Percentage of Patients Who Discontinue Treatment With Bimatoprost-Containing Eye Drops Prior to 12 Weeks of Treatment
NCT01646151 (8) [back to overview]	Intraocular Pressure (IOP) at Baseline
NCT01646151 (8) [back to overview]	IOP at Week 12
NCT01646151 (8) [back to overview]	Patient Assessment of Tolerability on a 4-Point Scale
NCT01646151 (8) [back to overview]	Physician Assessment of Patient Compliance Compared to Previous Therapy
NCT01646151 (8) [back to overview]	Physician Evaluation of IOP Lowering in the Study Eye(s)
NCT01646151 (8) [back to overview]	Physician Assessment of Tolerability on a 4-Point Scale
NCT01646151 (8) [back to overview]	Percentage of Patients Who Continue Treatment With Bimatoprost-Containing Eye Drops
NCT01664039 (8) [back to overview]	Percentage of Subjects Who Reached Target IOP at Each Visit
NCT01664039 (8) [back to overview]	Mean Change From Baseline in Intraocular Pressure (IOP) at Month 6
NCT01664039 (8) [back to overview]	Mean Change From Baseline in IOP at Week 6 and Month 3
NCT01664039 (8) [back to overview]	Number of Subjects With Change From Baseline in Ocular Hyperaemia by Grade at Each Visit
NCT01664039 (8) [back to overview]	Number of Subjects With Change From Baseline in Corneal Staining by Grade at Month 3 and Month 6
NCT01664039 (8) [back to overview]	Number of Subjects With Change From Baseline in Conjunctiva Staining by Grade at Month 3 and Month 6
NCT01664039 (8) [back to overview]	Mean Change From Baseline In Tear Film Break Up Time (TBUT) at Month 3 and Month 6
NCT01664039 (8) [back to overview]	Mean Change From Baseline in Ocular Surface Disease Index (OSDI) Score at Month 3 and Month 6
NCT01698554 (5) [back to overview]	Change From Baseline in Upper Eyelash Length as Measured Using Digital Image Analysis (DIA)
NCT01698554 (5) [back to overview]	Change From Baseline in Upper Eyelash Intensity (Darkness) as Measured Using DIA
NCT01698554 (5) [back to overview]	Percentage of Participants With at Least a 1-Grade Increase (Improvement) From Baseline in the Investigator's Assessment of Overall Eyelash Prominence (GEA)
NCT01698554 (5) [back to overview]	Change From Baseline in Upper Eyelash Thickness/Fullness as Measured Using DIA
NCT01698554 (5) [back to overview]	Percentage of Participants Satisfied or Very Satisfied in the Patient's Assessment of Overall Eyelash Satisfaction as Measured by the Eyelash Satisfaction Questionnaire (ESQ-9)
NCT01765764 (4) [back to overview]	Change From Baseline in Eyebrow Darkness as Measured Using DMSIA
NCT01765764 (4) [back to overview]	Change From Baseline in Eyebrow Fullness as Measured Using Digital Monitoring System Image Analysis (DMSIA)
NCT01765764 (4) [back to overview]	Percentage of Participants With at Least a 1-Grade Increase (Improvement) in the 4-Point Global Eyebrow Assessment (GEBA) Scale
NCT01765764 (4) [back to overview]	Percentage of Participants With 'Very Satisfied' or 'Mostly Satisfied' in Eyebrow Satisfaction Scale (ESS) Item #6
NCT01814761 (4) [back to overview]	Change From Baseline in Intraocular Pressure (IOP) in the Study Eye
NCT01814761 (4) [back to overview]	Overall Percent Change From Baseline in IOP
NCT01814761 (4) [back to overview]	Severity of Ocular Hyperemia in the Study Eye on a 5-Point Scale
NCT01814761 (4) [back to overview]	Percentage of Patients Who Discontinue Due to an Adverse Event
NCT01830140 (1) [back to overview]	Percentage of Patients With an Increase in Macroscopic Conjunctival Hyperemia in Either Eye
NCT01833741 (10) [back to overview]	Change From Baseline in IOP in the Study Eye of Previously Treated (Switched) Patients
NCT01833741 (10) [back to overview]	Change From Baseline in IOP in the Study Eye of Patients Treated With Adjunctive Therapy
NCT01833741 (10) [back to overview]	Percentage of Patients Discontinuing Due to Ocular Adverse Events
NCT01833741 (10) [back to overview]	Percent Change From Baseline in IOP in the Study Eye of Previously Treated (Switched) Patients
NCT01833741 (10) [back to overview]	Percent Change From Baseline in IOP in the Study Eye of Patients Treated With Adjunctive Therapy
NCT01833741 (10) [back to overview]	Percent Change From Baseline in Intraocular Pressure (IOP) in the Study Eye of Treatment-Naive Patients
NCT01833741 (10) [back to overview]	Percentage of Treatment-Naive Patients With Ocular Hyperemia
NCT01833741 (10) [back to overview]	Percentage of Previously Treated (Switched) Patients With Ocular Hyperemia
NCT01833741 (10) [back to overview]	Percentage of Patients Treated With Adjunctive Therapy With Ocular Hyperemia
NCT01833741 (10) [back to overview]	Change From Baseline in IOP in the Study Eye of Treatment-Naive Patients
NCT01853085 (8) [back to overview]	Patient Assessment of Tolerability on a 4-Point Scale
NCT01853085 (8) [back to overview]	Number of Patients Who Discontinue Treatment With Lumigan® UD Prior to 12 Weeks of Treatment
NCT01853085 (8) [back to overview]	Number of Patients Who Continue Treatment
NCT01853085 (8) [back to overview]	IOP in the Study Eye at Week 12
NCT01853085 (8) [back to overview]	Intraocular Pressure (IOP) in the Study Eye at Baseline
NCT01853085 (8) [back to overview]	Physician Assessment of Tolerability on a 4-Point Scale
NCT01853085 (8) [back to overview]	Physician Assessment of Patient Compliance Compared to Previous Treatment on a 3-Point Scale
NCT01853085 (8) [back to overview]	Physician Assessment of IOP-Lowering Effect in the Study Eye on a 3-Point Scale
NCT01863953 (3) [back to overview]	Change From Baseline in Average Eye Mean Diurnal IOP
NCT01863953 (3) [back to overview]	Change From Baseline in Average Eye Mean Diurnal Intraocular Pressure (IOP)
NCT01863953 (3) [back to overview]	Average Eye Mean Diurnal IOP
NCT01881126 (1) [back to overview]	Intraocular Pressure (IOP) in the Study Eye at 8 AM, 12 PM, and 4 PM
NCT01904721 (6) [back to overview]	Percentage of Participants in Each Response Category of the Subject Self Assessment in Alopecia (SSA) Score
NCT01904721 (6) [back to overview]	Change From Baseline in Target Area Hair Darkness (TAHD)
NCT01904721 (6) [back to overview]	Change From Baseline in Target Area Hair Count (TAHC)
NCT01904721 (6) [back to overview]	Percentage of Participants in Each Response Category of the Investigator Global Assessment (IGA) Score
NCT01904721 (6) [back to overview]	Percentage of Participants in Each Response Category of the Global Panel Review (GPR) Score
NCT01904721 (6) [back to overview]	Change From Baseline in Target Area Hair Width (TAHW)
NCT01915940 (6) [back to overview]	Change From Baseline in Intra-Ocular Pressure (IOP) at Week 12
NCT01915940 (6) [back to overview]	Change From Baseline in Intra-Ocular Pressure (IOP) at Week 2
NCT01915940 (6) [back to overview]	Change From Baseline in Intra-Ocular Pressure (IOP) at Week 6
NCT01915940 (6) [back to overview]	Change From Baseline in IOP at Month 4
NCT01915940 (6) [back to overview]	Change From Baseline in IOP at Month 6
NCT01915940 (6) [back to overview]	Change From Baseline in IOP at Month 5
NCT01976624 (2) [back to overview]	Change From Baseline in Intraocular Pressure (IOP)
NCT01976624 (2) [back to overview]	Number of Participants With Adverse Events and Adverse Drug Reactions
NCT01999348 (7) [back to overview]	Percentage of Patients Prescribed by the Physician to Continue Treatment
NCT01999348 (7) [back to overview]	Percentage of Patients Who Discontinued Treatment
NCT01999348 (7) [back to overview]	Change From Baseline in Intraocular Pressure (IOP) in the Study Eye
NCT01999348 (7) [back to overview]	Patient Assessment of Tolerability on a 4-Point Scale
NCT01999348 (7) [back to overview]	Physician Assessment of IOP-Lowering Effect in the Study Eye Using a 3-Point Scale
NCT01999348 (7) [back to overview]	Physician Assessment of Patient Compliance Compared to Previous Treatment on a 3-Point Scale
NCT01999348 (7) [back to overview]	Physician Assessment of Tolerability on a 4-Point Scale
NCT02020512 (1) [back to overview]	Change From Baseline in Intraocular Pressure (IOP) in the Study Eye
NCT02061683 (2) [back to overview]	Percentage of Patients With an Adverse Event of Conjunctival Hyperemia
NCT02061683 (2) [back to overview]	Intraocular Pressure (IOP) in the Study Eye
NCT02097719 (1) [back to overview]	Intraocular Pressure (IOP) in the Study Eye at 8 AM, 12 PM, and 4 PM
NCT02143843 (2) [back to overview]	Percentage of Participants With Ocular and Non-ocular Adverse Events (AE) by Severity
NCT02143843 (2) [back to overview]	Change From Baseline in Mean Intraocular Pressure (IOP)
NCT02170662 (3) [back to overview]	Percent Change in Target Area Total Hair Count
NCT02170662 (3) [back to overview]	Percent Change in the Target Area Terminal Hair Count
NCT02170662 (3) [back to overview]	Percent Change in the Target Area Vellus Hair Count
NCT02176356 (14) [back to overview]	Change From Baseline in Aging Appearance Using a 7-item Questionnaire
NCT02176356 (14) [back to overview]	Change From Baseline in Investigator's Assessment of Severity of Glabellar Lines (GLs) at Maximum Frown Using the Facial Wrinkle Scale (FWS)
NCT02176356 (14) [back to overview]	Change From Baseline in Investigator's Assessment of the Severity of Crow's Feet Lines (CFLs) at Maximum Smile Using the FWS
NCT02176356 (14) [back to overview]	Change From Baseline in Investigator's Global Eyelash Assessment Score (GEAS)
NCT02176356 (14) [back to overview]	Change From Baseline in Psychological Well-Being Using a 10-item Questionnaire
NCT02176356 (14) [back to overview]	Change From Baseline in Satisfaction With Facial Appearance Overall Using a 10-item Questionnaire
NCT02176356 (14) [back to overview]	Change From Baseline in Social Confidence Using an 8-item Questionnaire
NCT02176356 (14) [back to overview]	Change From Baseline in the Investigator's Assessment of the Participant's Nasolabial Folds Severity
NCT02176356 (14) [back to overview]	Change From Baseline in the Investigator's Assessment of the Participant's Oral Commissures Severity
NCT02176356 (14) [back to overview]	Change From Baseline in the Investigator's Assessment of the Participant's Overall Mid-Face Volume Deficit Using the 6-Point MFVDS
NCT02176356 (14) [back to overview]	Change From Baseline in the Investigator's Assessment of the Participant's Perioral Lines Severity
NCT02176356 (14) [back to overview]	Change From Baseline in the Participant Satisfaction With Appearance of Periorbital Area
NCT02176356 (14) [back to overview]	Participant's Self- Perception of Age (SPA)
NCT02176356 (14) [back to overview]	Change From Baseline in Age Appraisal Using a Visual Analogue Scale (VAS)
NCT02247804 (8) [back to overview]	IOP in the Study Eye at Week 2 (Hour 0)
NCT02247804 (8) [back to overview]	IOP in the Study Eye at Week 2 (Hour 2)
NCT02247804 (8) [back to overview]	IOP in the Study Eye at Week 6 (Hour 0)
NCT02247804 (8) [back to overview]	IOP in the Study Eye at Week 6 (Hour 2)
NCT02247804 (8) [back to overview]	Change From Baseline in IOP in the Study Eye
NCT02247804 (8) [back to overview]	Change From Baseline in IOP in the Study Eye at Week 12 (Hours 0 and 2)
NCT02247804 (8) [back to overview]	IOP in the Study Eye at Week 12 (Hour 0)
NCT02247804 (8) [back to overview]	IOP in the Study Eye at Week 12 (Hour 2)
NCT02250651 (8) [back to overview]	IOP in the Study Eye at Week 6 (Hour 2)
NCT02250651 (8) [back to overview]	Change From Baseline in IOP in the Study Eye
NCT02250651 (8) [back to overview]	IOP in the Study Eye at Week 12 (Hour 0)
NCT02250651 (8) [back to overview]	IOP in the Study Eye at Week 12 (Hour 2)
NCT02250651 (8) [back to overview]	IOP in the Study Eye at Week 2 (Hour 0)
NCT02250651 (8) [back to overview]	IOP in the Study Eye at Week 2 (Hour 2)
NCT02250651 (8) [back to overview]	IOP in the Study Eye at Week 6 (Hour 0)
NCT02250651 (8) [back to overview]	Change From Baseline in Intraocular Pressure (IOP) in the Study Eye to Week 12 (Hours 0 and 2)
NCT02358369 (13) [back to overview]	Percentage of Participants by Change From Baseline in Best-corrected Visual Acuity (BCVA) Categories at Week 8
NCT02358369 (13) [back to overview]	Percentage of Participants With Ocular and Non-ocular Adverse Events (AE) by Severity in Period A/B
NCT02358369 (13) [back to overview]	Percentage of Participants by Dilated Fundus Exam Pathology Grade at Week 12
NCT02358369 (13) [back to overview]	Percentage of Participants With Clinically Significant Change From Baseline in Slit-Lamp Examination Findings at Week 12
NCT02358369 (13) [back to overview]	Change From Baseline in Automated Visual Field at Week 12
NCT02358369 (13) [back to overview]	Change From Baseline in Intraocular Pressure (IOP) at Week 8
NCT02358369 (13) [back to overview]	Percentage of Participants With Ocular and Non-ocular Adverse Events (AE) by Severity in Period C
NCT02358369 (13) [back to overview]	Change From Baseline in IOP at Week 12
NCT02358369 (13) [back to overview]	Change From Baseline in IOP at Week 2
NCT02358369 (13) [back to overview]	Change From Baseline in IOP at Week 6
NCT02358369 (13) [back to overview]	Change From Baseline in IOP in Period C
NCT02358369 (13) [back to overview]	Dilated Fundus Exam: Cup-to-Disc-Ratio
NCT02358369 (13) [back to overview]	Percentage of Participants by Change From Baseline in Best-corrected Visual Acuity (BCVA) Categories at Week 12
NCT02419508 (7) [back to overview]	Mean Diurnal IOP at Week 6
NCT02419508 (7) [back to overview]	Mean Percentage Change From Baseline at 09:00 at Week 6
NCT02419508 (7) [back to overview]	Mean Percentage Change From Baseline in Diurnal IOP at Week 6
NCT02419508 (7) [back to overview]	Mean Percentage Change From Baseline in IOP at 11:00 at Week 6
NCT02419508 (7) [back to overview]	Mean Change From Baseline in IOP at 09:00 at Week 6
NCT02419508 (7) [back to overview]	Mean Change From Baseline in IOP at 11:00 at Week 6
NCT02419508 (7) [back to overview]	Mean Change From Baseline (on PGA) in Diurnal IOP (Mean of 09:00 and 11:00 Time Points) at Week 6
NCT02448043 (5) [back to overview]	Number of Days Until the First Nail Chipped
NCT02448043 (5) [back to overview]	Intraocular Pressure at 30 Days of Treatment
NCT02448043 (5) [back to overview]	Change From Baseline in Nail Length of Hands
NCT02448043 (5) [back to overview]	Nail Brittleness at 30 Days of Treatment
NCT02448043 (5) [back to overview]	Change From Baseline in Nail Length of Digits
NCT02537015 (1) [back to overview]	Percentage of Participants With Ocular and Non-ocular Adverse Events (AE) by Severity
NCT02636946 (7) [back to overview]	Change From Baseline in IOP at Week 12
NCT02636946 (7) [back to overview]	Change From Baseline in Intraocular Pressure (IOP) at Week 24
NCT02636946 (7) [back to overview]	Percentage of Participants With Eyes Achieving a ≥ 20% Reduction in IOP
NCT02636946 (7) [back to overview]	Change From Baseline in IOP at Weeks 8, 15, and 20
NCT02636946 (7) [back to overview]	Time to Initial Use of Nonstudy IOP-lowering Treatment as Determined by the Investigator
NCT02636946 (7) [back to overview]	Intraocular Pressure (IOP) at Baseline
NCT02636946 (7) [back to overview]	Change From Baseline in IOP at Week 4
NCT02742649 (7) [back to overview]	Intraocular Pressure (IOP) on Day 8
NCT02742649 (7) [back to overview]	IOP on Day 70
NCT02742649 (7) [back to overview]	IOP on Day 49
NCT02742649 (7) [back to overview]	IOP on Day 28
NCT02742649 (7) [back to overview]	Number of Participants With Ocular and Non-Ocular Adverse Events
NCT02742649 (7) [back to overview]	IOP During Open Label Period
NCT02742649 (7) [back to overview]	IOP on Day 16
NCT02830776 (2) [back to overview]	Change in Patient Satisfaction
NCT02830776 (2) [back to overview]	Graded Change in Dermatochalasis
NCT03825380 (1) [back to overview]	Intra-Ocular Pressure
NCT04285580 (3) [back to overview]	Change From Baseline in Time-Matched Intraocular Pressure (IOP) for Bimatoprost SR Treated Eyes
NCT04285580 (3) [back to overview]	Number of Patients Experiencing One or More Treatment Emergent Adverse Events (TEAEs)
NCT04285580 (3) [back to overview]	Change From Baseline in Range of Intraocular Pressure (IOP) for Bimatoprost SR-treated Eyes

Tolerability - Conjunctival Hyperemia

Conjunctival Hyperemia: Number of participants with at least 1 grade increase in severity from baseline. A five grade scale from 0 to 3 (0 = none, +0.5 = trace, 1 = mild, 2 = moderate, 3 = severe) (NCT00440011)
Timeframe: Month 3

Intervention	participants (Number)
Bimatoprost	15
Travoprost	22

Intervention	millimeters of mercury (mmHg) (Mean)
	Baseline, 8AM	Month 1, 8AM
Bimatoprost Eye Drops	18.2	-1.0
Placebo	18.0	3.6

Intervention	Scores on a Scale (Mean)
	Baseline	Month 3
Bimatoprost 0.03%	0.59	0.15
Latanoprost 0.005%	0.70	-0.18
Travoprost 0.004%	0.48	-0.07

Intervention	millimeters of mercury (mmHg) (Mean)
	Baseline	Week 18
Bimatoprost 0.03% Eye Drops	21.90	-5.77
Latanoprost 0.005% Eye Drops	22.16	-5.09

Intervention	millimeters of mercury (mmHg) (Mean)
	Baseline	Week 12
Bimatoprost 0.03% Eye Drops	21.90	-5.64
Latanoprost 0.005% Eye Drops	22.16	-4.89

Intervention	score on a scale (Mean)
	Day 1 (Baseline)	Week 1	Week 4	Week 8	Week 12	Week 16 (Primary Endpoint)
Bimatoprost 0.03% Solution	4.18	0.06	-0.25	-0.90	-1.48	-1.89
Vehicle Solution	4.16	-0.06	-0.35	-0.57	-0.67	-0.70

Intervention	Lab* (Mean)
	Upper Lid	Lower Lid	Cheek/Face
Lumigan	-0.90	-0.37	0.30
Travatan	-0.90	0.17	0.51
Xalatan	-1.42	0.48	0.55

Intervention	Millimeters of mercury (mmHg) (Mean)
	Baseline	Change from Baseline at 1 Year
Lumigan®	20.8	-4.8
Travatan®	20.3	-4.3
Xalatan®	20.6	-4.3

Intervention	mm (Mean)
Bimatoprost Mixed With Gonak Into a Gel Suspension	2
Control Group	1.1

Intervention	Millimeters of Mercury (mmHg) (Mean)
	Baseline - Hour 0	Change from Baseline at Day 14 - Hour 0
AGN-210669 Ophthalmic Solution, 0.025%	25.341	-4.068
AGN-210669 Ophthalmic Solution, 0.05%	25.318	-5.197
AGN-210669 Ophthalmic Solution, 0.075%	25.350	-5.807
AGN-210669 Vehicle Ophthalmic Solution	25.507	-2.382
Bimatoprost Ophthalmic Solution 0.03%	24.650	-6.575

Intervention	Percentage of Patients (Number)
AGN 210669 Non-preserved Ophthalmic Solution, 0.075%	62.9
AGN-210669 Ophthalmic Solution, 0.05%	57.6
AGN-210669 Ophthalmic Solution, 0.025%	30.3
Bimatoprost Ophthalmic Solution 0.03%	63.3
AGN-210669 Vehicle Ophthalmic Solution	2.8

Intervention	Millimeters squared (mm^2) (Mean)
	Baseline	Change from Baseline at Month 4
Bimatoprost 0.03%	0.67	0.59
Vehicle	0.82	-0.07

Intervention	Millimeters of Mercury (mmHg) (Mean)
	Baseline - Hour 0	Change from Baseline at Day 29 - Hour 0
AGN-210669 Ophthalmic Solution, 0.05%	25.39	-5.66
AGN-210669 Ophthalmic Solution, 0.075%	25.18	-7.65
AGN-210669 Ophthalmic Solution, 0.1%	25.88	-7.50
Bimatoprost Ophthalmic Solution 0.03%	25.73	-8.57

Intervention	mmHg (Mean)
High Dose Drug Device/ Bimatoprost 0.03%	-4.16
Low Dose Drug Device / Bimatoprost 0.03%	-4.57
Placebo Device / Bimatoprost 0.03%	-0.60

Intervention	Percentage of participants (Number)
Bimatoprost Ophthalmic Solution 0.03%	70.8
Vehicle Sterile Solution	26.1

Intervention	Percentage of participants (Number)
Bimatoprost Ophthalmic Solution 0.03%	35.4
Vehicle Sterile Solution	43.5

Intervention	Scores on a Scale (Mean)
	If Avail, How Likely Would You Continue to Use It?	If Avail, How Likely Would You Recommend It?
Bimatoprost Ophthalmic Solution 0.005%	4.1	4.1
Bimatoprost Ophthalmic Solution 0.015%	4.2	4.2
Bimatoprost Ophthalmic Solution 0.03%	4.1	4.4

Intervention	Units on a Scale (Mean)
	Baseline	Change from Baseline at Month 3
Bimatoprost Ophthalmic Solution 0.005%	157.14	-18.75
Bimatoprost Ophthalmic Solution 0.015%	154.41	-26.55
Bimatoprost Ophthalmic Solution 0.03%	162.41	-29.61

Intervention	Percentage of Subjects (Number)
Bimatoprost Ophthalmic Solution 0.005%	52.8
Bimatoprost Ophthalmic Solution 0.015%	79.4
Bimatoprost Ophthalmic Solution 0.03%	85.3

Intervention	Millimeters of mercury (mmHg) (Mean)
	Baseline	Change from Baseline at Week 4
0.03% Bimatoprost and 0.5% Timolol in Separate Bottles	24.87	-8.93
0.03% Bimatoprost/0.5% Timolol in Same Bottle	25.20	-9.38

Intervention	Millimeters of Mercury (mmHg) (Mean)
	Week 6 Hour 0	Week 6 Hour 2	Week 6 Hour 8
Bimatoprost 0.03% Formulation B Ophthalmic Solution	17.16	16.52	16.56
Bimatoprost 0.03% Ophthalmic Solution	17.08	16.45	16.32

bimatoprost

Description

Cross-References

Synonyms (76)

Research Excerpts

Overview

Effects

Actions

Treatment

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (2)

Drug Classes (1)

Protein Targets (4)

Inhibition Measurements

Biological Processes (41)

Molecular Functions (24)

Ceullar Components (17)

Bioassays (23)

Research

Studies (543)

Market Indicators

Research Demand Index: 59.04

Study Types

Clinical Trials (149)

Trial Overview

Trial Outcomes

Tolerability - Conjunctival Hyperemia

Intraocular Pressure (IOP)

Change From Baseline in Mean Peak Macroscopic Conjunctival Hyperemia at Month 1

Percentage of Patients With an Increase in Macroscopic Conjunctival Hyperemia in Either Eye at Month 1

Percentage of Physicians Who Were Very or Extremely Willing to Continue Patient on Drug, if Drug Were Marketed at Month 1

Change From Baseline in Mean Intraocular Pressure (IOP) at Month 1

Percentage of Patients Who Were Very or Extremely Willing to Use This Glaucoma Medication at Month 1

Percentage of Patients Who Reported No Change in the Appearance of Their Eyes Since the Beginning of the Study at Month 1

Change From Baseline in Corneal Staining With Fluorescein at Month 3

Change From Baseline in Mean Conjunctival Hyperemia Scores at Month 3

Change From Baseline in Tear Break-Up Time (TBUT) at Month 3

Change From Baseline in Mean Diurnal Intraocular Pressure (IOP) at Week 18

Change From Baseline in Mean Diurnal Intraocular Pressure (IOP) at Week 12

Patient Reported Outcome: Overall Satisfaction With Eyelashes (Single Item) in Terms of Change From Baseline to Week 16

Percentage of Participants Experiencing at Least a 1-grade Increase on the Global Eyelash Assessment (GEA) Scale From Baseline to Week 16

Upper Eyelash Darkness as Measured by Digital Image Analysis in Terms of Change From Baseline to Week 16

Upper Eyelash Length as Measured by Digital Image Analysis in Terms of Change From Baseline to Week 16

Upper Eyelash Thickness as Measured by Digital Image Analysis in Terms of Change From Baseline to Week 16

Percentage of Participants Experiencing at Least a 1-grade Increase on the Global Eyelash Assessment (GEA) Scale From Baseline to Week 20 (Post-treatment)

Patient Reported Outcome: Overall Satisfaction With Eyelashes (Single Item) in Terms of Change From Baseline to Week 20 (Post-treatment)

Upper Eyelash Darkness as Measured by Digital Image Analysis in Terms of Change From Baseline to Week 20 (Post-treatment)

Upper Eyelash Length as Measured by Digital Image Analysis in Terms of Change From Baseline to Week 20 (Post-treatment)

Upper Eyelash Thickness as Measured by Digital Image Analysis in Terms of Change From Baseline to Week 20 (Post-treatment)

The Extent of Latanoprost, Bimatoprost and Travoprost Induced Periocular Skin Hyperpigmentation Over a One Year Time Course in Newly Diagnosed Primary Open Angle and Ocular Hypertension Patients.

Change From Baseline in Bilateral Intraocular Pressure (IOP) at One Year

Efficacy of Bimatoprost in Lengthening of Eyelashes

Change From Baseline in Average Eye Intraocular Pressure (IOP)

Percentage of Patients With ≥ 20% Reduction From Baseline in Diurnal IOP

Percentage of Treatment Responders at Month 4

Change From Baseline in Average Progressive Upper Eyelash Thickness at Month 4

Percentage of Subjects With at Least a 1-Grade Improvement in Global Eyelash Assessment (GEA) Score at Month 4

Change From Baseline in Upper Eyelash Length at Month 4

Change From Baseline in Upper Eyelash Darkness at Month 4

Percentage of Treatment Responders in Overall Eyelash Prominence at Month 4

Change From Baseline in Average Eye Intraocular Pressure (IOP)

Mean Change in Intraocular Pressure at Day 1

Percentage of Participants With at Least a 1-Grade Improvement From Baseline in the Global Eyebrow Assessment (GEA) Score

Percentage of Participants With Adverse Events

Change From Baseline Upper Eyelash Length as Measured by Digital Image Analysis (DIA)

Change From Baseline in Upper Eyelash Thickness as Measured by DIA

Change From Baseline in Upper Eyelash Darkness as Measured by DIA

Treatment Satisfaction Questionnaire Score at Month 3

Change From Baseline in Upper Eyelash Darkness (in Intensity Units) at Month 3

Change From Baseline in Upper Eyelash Thickness at Month 3

Change From Baseline in the Confidence, Attractiveness, and Professionalism (CAP) Domain Scores at Month 3

Change From Baseline in Overall Eyelash Satisfaction at Month 3

Change From Baseline in Eyelash Length at Month 3

Percentage of Subjects With a Clinical Response in Overall Eyelash Prominence on the Global Eyelash Assessment (GEA) at Month 3

The Difference of Change From Baseline of Mean Diurnal Intraocular Pressure (IOP) Between the Two Treatment Groups at Week 4

Average Eye IOP at Week 6

Intervention	Millimeters of Mercury (mmHg) (Mean)
	Baseline Hour 0	Baseline Hour 2	Baseline Hour 8	Change from Baseline Hour 0 at Week 12	Change from Baseline Hour 2 at Week 12	Change from Baseline Hour 8 at Week 12
Bimatoprost 0.03% Formulation B Ophthalmic Solution	24.90	23.79	22.81	-7.49	-7.06	-5.93
Bimatoprost 0.03% Ophthalmic Solution	24.86	23.78	22.80	-7.77	-7.11	-6.06

Intervention	Millimeters of Mercury (mmHg) (Mean)
	Week 2 Hour 0	Week 2 Hour 2	Week 2 Hour 8
Bimatoprost 0.03% Formulation B Ophthalmic Solution	17.40	16.68	16.61
Bimatoprost 0.03% Ophthalmic Solution	17.14	16.43	16.39

Intervention	Millimeters of Mercury (mmHg) (Mean)
	Baseline - Hour 0	Baseline - Hour 2	Baseline - Hour 4	Baseline - Hour 6	Baseline - Hour 8	Baseline - Hour 12	Change from Baseline at Day 29 - Hour 0	Change from Baseline at Day 29 - Hour 2	Change from Baseline at Day 29 - Hour 4	Change from Baseline at Day 29 - Hour 6	Change from Baseline at Day 29 - Hour 8	Change from Baseline at Day 29 - Hour 12
Part 2, AGN-210961 Formulation 7	24.63	23.40	22.25	21.97	21.28	20.72	-7.44	-7.40	-6.25	-6.31	-6.15	-5.74
Part 2, Bimatoprost Ophthalmic Solution 0.03%	24.62	23.70	22.51	22.38	21.48	20.94	-8.63	-8.51	-7.39	-6.92	-6.31	-5.10

Intervention	Days (Median)
Bimatoprost 20 µg Generation 2, Bimatoprost 0.03%	328
Bimatoprost 15 µg Generation 2, Bimatoprost 0.03%	265
Bimatoprost 10 µg Generation 2, Bimatoprost 0.03%	273
Bimatoprost 6 µg Generation 2, Bimatoprost 0.03%	391.5
Bimatoprost 15 μg Generation 1, Bimatoprost 0.03%	411
Bimatoprost 10 μg Generation 1, Bimatoprost 0.03%	237

Intervention	Millimeters of Mercury (mmHg) (Mean)
	Baseline Hour 0,	Week 4, Hour 0	Week 12, Hour 0	Month 6, Hour 0	Month 12, Hour 0	Month 18, Hour 0	Month 24, Hour 0
Bimatoprost 10 μg Generation 1, Bimatoprost 0.03%	24.22	-7.33	-7.00	-5.40	-5.71	-9.75	-5.50
Bimatoprost 10 µg Generation 2, Bimatoprost 0.03%	24.48	-7.18	-6.82	-5.38	-6.00	-7.70	-7.40
Bimatoprost 15 μg Generation 1, Bimatoprost 0.03%	23.73	-5.50	-5.95	-3.94	-5.80	-4.25	-8.50
Bimatoprost 15 µg Generation 2, Bimatoprost 0.03%	25.14	-7.80	-7.02	-6.50	-5.64	-6.92	-7.30
Bimatoprost 20 µg Generation 2, Bimatoprost 0.03%	26.57	-8.83	-7.92	-5.65	-9.00	-6.00	-5.75
Bimatoprost 6 µg Generation 2, Bimatoprost 0.03%	25.14	-7.09	-6.53	-6.81	-5.38	-6.93	-5.70

Intervention	Millimeters of Mercury (mmHg) (Mean)
	Baseline, Hour 0	Week 4, Hour 0	Week 12, Hour 0	Month 6, Hour 0
Bimatoprost 10 μg Generation 1, Bimatoprost 0.03%	24.22	17.00	17.23	18.80
Bimatoprost 10 µg Generation 2, Bimatoprost 0.03%	24.48	17.55	17.61	19.35
Bimatoprost 15 μg Generation 1, Bimatoprost 0.03%	23.73	18.23	17.77	19.44
Bimatoprost 15 µg Generation 2, Bimatoprost 0.03%	25.14	17.45	18.12	17.90
Bimatoprost 20 µg Generation 2, Bimatoprost 0.03%	26.57	17.73	17.71	19.10
Bimatoprost 6 µg Generation 2, Bimatoprost 0.03%	25.14	17.53	18.03	17.35

Intervention	mm Hg (Mean)
	Week 12_Hour 0	Week 12_Hour 2	Week 12_Hour 8
Bimatoprost/Timolol Fixed Combination Ophthalmic Solution	16.56	16.37	16.09
Bimatoprost/Timolol Formulation A	16.29	16.18	15.85

Intervention	mm Hg (Mean)
	Baseline_Hour 0	Baseline_Hour 2	Baseline_Hour 8	Change from baseline at Week 12_Hour 0	Change from baseline at Week 12_Hour 2	Change from baseline at Week 12_Hour 8
Bimatoprost/Timolol Fixed Combination Ophthalmic Solution	25.30	24.61	23.80	-8.51	-8.08	-7.52
Bimatoprost/Timolol Formulation A	25.34	24.71	23.81	-8.94	-8.44	-7.87

Intervention	mm Hg (Mean)
	Week 6_Hour 0	Week 6_Hour 2	Week 6_Hour 8
Bimatoprost/Timolol Fixed Combination Ophthalmic Solution	16.31	16.17	15.82
Bimatoprost/Timolol Formulation A	16.28	15.90	15.71

Intervention	mm Hg (Mean)
	Week 2_Hour 0	Week 2_Hour 2	Week 2_Hour 8
Bimatoprost/Timolol Fixed Combination Ophthalmic Solution	16.49	16.23	15.83
Bimatoprost/Timolol Formulation A	16.23	16.05	15.49